CRBN

UniProt ID: Q96SW2
Organism: Homo sapiens
Review Status: COMPLETE
๐Ÿ“ Provide Detailed Feedback

Gene Description

CRBN (cereblon) is the substrate-recognition subunit of a CRL4 cullin-RING E3 ubiquitin ligase, the DCX/CRL4(CRBN) complex composed of DDB1, CUL4A or CUL4B, RBX1 and CRBN. Through an N-terminal Lon-protease-like domain it binds the adaptor DDB1, and through a C-terminal thalidomide-binding (CULT) domain that coordinates a structural Zn2+ ion it recruits substrate proteins for ubiquitination and subsequent proteasomal degradation. Endogenous substrates include MEIS2, glutamine synthetase (GLUL) and ILF2, and the complex is required for normal limb outgrowth and FGF8 expression in vertebrates. CRBN also regulates neuronal large-conductance Ca2+-activated potassium (BK) channels via interaction with KCNT1, contributing to presynaptic glutamate release, memory and learning; loss-of-function variants cause autosomal recessive intellectual developmental disorder. The CULT domain is the direct molecular target of thalidomide, lenalidomide and pomalidomide (IMiDs) and of newer molecular-glue and PROTAC degraders, which act as molecular glues that reprogram CRBN substrate specificity to recruit neosubstrates such as IKZF1, IKZF3, SALL4, CK1alpha and GSPT1 for degradation. CRBN is expressed widely and most highly in brain, and localizes to cytoplasm, nucleus and peripheral membranes.

Existing Annotations Review

GO Term Evidence Action Reason
GO:0005634 nucleus
IBA
GO_REF:0000033
ACCEPT
Summary: CRBN is found in the nucleus as well as the cytoplasm by direct immunolocalization, consistent with this phylogenetic transfer.
Reason: Nuclear localization is supported by direct experimental evidence (PMID:20223979, IDA) and is consistent with the substrate-receptor role; the IBA transfer to nucleus is reasonable. It is a localization rather than the core molecular function.
Supporting Evidence:
PMID:20223979
CRBN is a thalidomide-binding protein that forms an E3 ubiquitin ligase complex with DDB1 and Cul4A; subcellular localization studies place it in the nucleus and cytoplasm.
GO:0030177 positive regulation of Wnt signaling pathway
IBA
GO_REF:0000033
KEEP AS NON CORE
Summary: CRBN promotes Wnt-induced, IMiD-independent degradation of CK1alpha (a negative regulator of Wnt), and is required for physiological Wnt signaling with conserved Wnt phenotypes in zebrafish and Drosophila.
Reason: This regulatory role is experimentally supported (PMID:34489457) and conserved, so the phylogenetic transfer is justified, but it is a downstream physiological consequence of the E3-ligase activity rather than CRBN's core substrate-receptor function.
Supporting Evidence:
PMID:34489457
CRBN is required for physiological Wnt signaling, as modulation of CRBN in zebrafish and Drosophila yields Wnt-driven phenotypes.
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
IBA
GO_REF:0000033
ACCEPT
Summary: As the substrate receptor of CRL4(CRBN), CRBN targets substrates for ubiquitination and proteasomal degradation; this is a core biological process for the gene.
Reason: Directly supported by experimental evidence (PMID:20223979 IMP; PMID:26131937 showing cullin/proteasome-dependent substrate degradation) and a central function.
Supporting Evidence:
PMID:26131937
The lenalidomide-dependent decrease in CK1alpha protein level was abrogated by treatment with the proteasome inhibitor MG132 and the NEDD8-activating enzyme inhibitor MLN4924, which interferes with the activity of cullin-RING E3 ubiquitin ligases, implicating proteasome- and cullin-dependent degradation of CK1alpha.
GO:0060173 limb development
IBA
GO_REF:0000033
KEEP AS NON CORE
Summary: The CRBN-containing CRL4 complex is required for normal limb outgrowth and FGF8 expression in zebrafish and chicks; thalidomide inhibition of this activity underlies its teratogenic limb defects.
Reason: This developmental phenotype is supported (PMID:20223979) and explains thalidomide teratogenicity, but it is a tissue/developmental consequence of the core E3-ligase function rather than the molecular function itself.
Supporting Evidence:
PMID:20223979
CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks.
GO:0031464 Cul4A-RING E3 ubiquitin ligase complex
IBA
GO_REF:0000033
ACCEPT
Summary: CRBN is the substrate-receptor component of the CUL4A-RBX1-DDB1-CRBN (CRL4) E3 ubiquitin ligase complex.
Reason: Core, well-established complex membership supported by direct experimental and structural evidence (PMID:20223979 IDA, PMID:25108355).
Supporting Evidence:
PMID:20223979
CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A.
GO:0005634 nucleus
IEA
GO_REF:0000044
ACCEPT
Summary: Nuclear localization, transferred from UniProt subcellular location; corroborated by direct immunolocalization (PMID:20223979).
Reason: Redundant with the experimentally supported IDA nucleus annotation; localization, not core function.
Supporting Evidence:
PMID:20223979
Subcellular localization analysis showed CRBN in the nucleus and cytoplasm.
GO:0005737 cytoplasm
IEA
GO_REF:0000044
ACCEPT
Summary: Cytoplasmic localization, transferred from UniProt subcellular location; corroborated by direct immunolocalization (PMID:20223979).
Reason: Redundant with the experimentally supported IDA cytoplasm annotation; localization, not core function.
Supporting Evidence:
PMID:20223979
Subcellular localization analysis showed CRBN in the nucleus and cytoplasm.
GO:0016020 membrane
IEA
GO_REF:0000044
KEEP AS NON CORE
Summary: CRBN is annotated as a peripheral membrane protein (by similarity), consistent with its interaction with membrane ion channels such as KCNT1/BK channels.
Reason: The very general "membrane" term reflects a peripheral membrane association (by similarity, UniProt) related to its channel-regulatory role; retained as a non-core location but uninformative as to function.
Supporting Evidence:
file:human/CRBN/CRBN-uniprot.txt
SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Membrane; Peripheral membrane protein.
GO:0005515 protein binding
IPI
PMID:25416956
A proteome-scale map of the human interactome network.
MARK AS OVER ANNOTATED
Summary: Bare protein binding from a high-throughput binary interactome map (HuRI), reporting interactions with RBPMS and PAK5.
Reason: GO:0005515 protein binding is uninformative and these high-throughput interactors (RBPMS, PAK5) have no established functional relationship to CRBN's E3-ligase role; per curation guidance bare protein binding should not be retained as informative.
Supporting Evidence:
PMID:25416956
A proteome-scale map of the human interactome network.
GO:0005515 protein binding
IPI
PMID:26131937
Lenalidomide induces ubiquitination and degradation of CK1ฮฑ ...
MARK AS OVER ANNOTATED
Summary: Protein-binding annotation derived from the lenalidomide study; the interactors are DDB1 (complex partner) and CK1alpha (a strictly IMiD-induced neosubstrate).
Reason: The underlying interactions are biologically meaningful (DDB1 defines complex membership; CK1alpha is a lenalidomide-induced neosubstrate), but the generic protein binding term is uninformative; the meaningful content is captured by the CRL4 complex-membership and ubiquitination/catabolism annotations and proposed substrate-adaptor MF.
Supporting Evidence:
PMID:26131937
Lenalidomide induces the ubiquitination of casein kinase 1A1 (CK1alpha) by the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4(CRBN)).
GO:0005515 protein binding
IPI
PMID:26909574
Structural basis of lenalidomide-induced CK1ฮฑ degradation by...
MARK AS OVER ANNOTATED
Summary: Protein-binding annotation from the structural study of the DDB1-CRBN-lenalidomide-CK1alpha complex; interactors are DDB1 and the IMiD-dependent neosubstrate CK1alpha.
Reason: CK1alpha binding to CRL4(CRBN) is strictly IMiD-dependent (a drug-induced neosubstrate), and DDB1 binding is captured by complex membership; the generic protein binding term itself is uninformative.
Supporting Evidence:
PMID:26909574
We show that CK1alpha binding to CRL4(CRBN) is strictly dependent on the presence of an IMiD.
GO:0005515 protein binding
IPI
PMID:31515488
Extensive disruption of protein interactions by genetic vari...
MARK AS OVER ANNOTATED
Summary: Bare protein binding from a large-scale interaction-perturbation screen, reporting an interaction with PAK5.
Reason: Uninformative generic term from a high-throughput screen with no established functional link to CRBN biology.
Supporting Evidence:
PMID:31515488
Extensive disruption of protein interactions by genetic variants across the allele frequency spectrum in human populations.
GO:0005515 protein binding
IPI
PMID:32296183
A reference map of the human binary protein interactome.
MARK AS OVER ANNOTATED
Summary: Bare protein binding from a binary human interactome reference map (HuRI), reporting an interaction with MISP.
Reason: Uninformative generic term from a high-throughput map with no established functional relationship to CRBN.
Supporting Evidence:
PMID:32296183
A reference map of the human binary protein interactome.
GO:0005515 protein binding
IPI
PMID:32814053
Interactome Mapping Provides a Network of Neurodegenerative ...
MARK AS OVER ANNOTATED
Summary: Bare protein binding from a neurodegenerative-disease interactome screen, reporting interactions with PMP22, KLF11 and COL26A1.
Reason: Uninformative generic term from a high-throughput screen with no established functional link to CRBN's E3-ligase function.
Supporting Evidence:
PMID:32814053
Interactome mapping providing a network of neurodegenerative-disease proteins, reporting CRBN interactions including with PMP22, KLF11 and COL26A1.
GO:0005515 protein binding
IPI
PMID:35271311
OpenCell: Endogenous tagging for the cartography of human ce...
MARK AS OVER ANNOTATED
Summary: Protein-binding annotation from the OpenCell endogenous-tagging study, reporting interaction with DDB1.
Reason: The DDB1 interaction is biologically central (it defines CRBN's incorporation into CRL4), but the generic protein binding term is uninformative; complex membership is already captured by the Cul4-RING complex annotations.
Supporting Evidence:
PMID:35271311
OpenCell: Endogenous tagging for the cartography of human cellular organization.
GO:0031333 negative regulation of protein-containing complex assembly
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: Transferred by orthology from rat Crbn (Q56AP7), reflecting CRBN's regulation of BK channel assembly/surface expression via KCNT1.
Reason: The underlying biology (CRBN regulating ion-channel complex assembly) is supported in rodent models, but this is a peripheral neuronal role transferred by orthology, not the core E3-ligase function.
Supporting Evidence:
file:human/CRBN/CRBN-uniprot.txt
Likely to function by regulating the assembly and neuronal surface expression of BK channels via its interaction with KCNT1.
GO:0031334 positive regulation of protein-containing complex assembly
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: Transferred by orthology from rat Crbn (Q56AP7); reflects CRBN's role in BK channel assembly/surface expression.
Reason: As with the negative-regulation counterpart, this is an ortholog-transferred peripheral neuronal role rather than the core E3 function; retained as non-core.
Supporting Evidence:
file:human/CRBN/CRBN-uniprot.txt
Likely to function by regulating the assembly and neuronal surface expression of BK channels via its interaction with KCNT1.
GO:0034766 negative regulation of monoatomic ion transmembrane transport
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: CRBN negatively regulates large-conductance Ca2+-activated K+ (BK) channels, maintaining presynaptic glutamate release and cognition; annotation transferred by orthology from rat Crbn.
Reason: Supported by rodent functional studies (PMID:29530986; UniProt FUNCTION) and explains MRT2-related cognitive phenotypes, but is a distinct neuronal role separate from the core E3-ligase function.
Supporting Evidence:
file:human/CRBN/CRBN-uniprot.txt
Maintains presynaptic glutamate release and consequently cognitive functions, such as memory and learning, by negatively regulating large-conductance calcium-activated potassium (BK) channels in excitatory neurons.
GO:0035641 locomotory exploration behavior
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: Behavioral term transferred by orthology from mouse Crbn (Q8C7D2).
Reason: Reflects organism-level behavioral phenotypes of rodent Crbn (consistent with CRBN's neuronal/BK-channel role) but is far removed from the molecular function and rests only on ortholog transfer.
Supporting Evidence:
file:human/CRBN/CRBN-uniprot.txt
May also be involved in regulating anxiety-like behaviors via a BK channel-independent mechanism (By similarity).
GO:0044325 transmembrane transporter binding
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: Reflects CRBN's interaction with the KCNT1 channel and the BK channel, transferred by orthology from rat Crbn.
Reason: A more informative MF than bare protein binding (channel binding underlies CRBN's neuronal role) and supported by interaction data, but peripheral to the core substrate-receptor function and based on ortholog transfer.
Supporting Evidence:
file:human/CRBN/CRBN-uniprot.txt
Likely to function by regulating the assembly and neuronal surface expression of BK channels via its interaction with KCNT1.
GO:0048471 perinuclear region of cytoplasm
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: Perinuclear cytoplasmic localization transferred by orthology from rat Crbn.
Reason: A plausible sub-cytoplasmic localization consistent with the experimentally supported cytoplasm annotation, but based only on ortholog transfer and not core function.
Supporting Evidence:
file:human/CRBN/CRBN-uniprot.txt
SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Membrane; Peripheral membrane protein.
GO:0016567 protein ubiquitination
IEA
GO_REF:0000041
ACCEPT
Summary: As the substrate receptor of CRL4(CRBN), CRBN mediates ubiquitination of target proteins; this UniPathway-mapped term is a core process.
Reason: Directly supported by experimental evidence (PMID:20223979 IMP) and central to CRBN function.
Supporting Evidence:
PMID:20223979
CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks.
GO:0031464 Cul4A-RING E3 ubiquitin ligase complex
NAS
PMID:25108355
Structure of the human Cereblon-DDB1-lenalidomide complex re...
ACCEPT
Summary: CRBN is a component of the CUL4A variant CRL4-CRBN E3 ubiquitin ligase complex (ComplexPortal CPX-2759).
Reason: Core complex membership; structurally and biochemically established (PMID:25108355 Cul4-Rbx1-DDB1-Cereblon complex). Redundant with the IDA annotation to the same term.
Supporting Evidence:
PMID:25108355
The Cul4-Rbx1-DDB1-Cereblon E3 ubiquitin ligase complex is the target of thalidomide, lenalidomide and pomalidomide.
GO:0031465 Cul4B-RING E3 ubiquitin ligase complex
NAS
PMID:25108355
Structure of the human Cereblon-DDB1-lenalidomide complex re...
ACCEPT
Summary: CRBN is also a component of the CUL4B variant CRL4-CRBN E3 ubiquitin ligase complex (ComplexPortal CPX-2762).
Reason: CRBN can assemble with either CUL4A or CUL4B; the CUL4B-variant complex is documented in ComplexPortal and is a valid core complex membership.
Supporting Evidence:
file:human/CRBN/CRBN-uniprot.txt
ComplexPortal; CPX-2762; CRL4-CRBN E3 ubiquitin ligase complex, CUL4B variant.
GO:0030177 positive regulation of Wnt signaling pathway
IMP
PMID:34489457
The E3 ubiquitin ligase component, Cereblon, is an evolution...
KEEP AS NON CORE
Summary: CRBN mediates Wnt-induced, IMiD-independent degradation of CK1alpha (a negative regulator of Wnt) and is required for physiological Wnt signaling.
Reason: Experimentally supported (PMID:34489457) and conserved, but a downstream physiological consequence of the E3-ligase activity rather than CRBN's core molecular function.
Supporting Evidence:
PMID:34489457
Herein we demonstrate that Wnt, the extracellular ligand of an essential signal transduction pathway, promotes the CRBN-dependent degradation of a subset of proteins.
GO:0005829 cytosol
TAS
Reactome:R-HSA-9681169
ACCEPT
Summary: Cytosolic localization from Reactome (CRBN binds IMiDs), consistent with the experimentally supported cytoplasm annotation.
Reason: Consistent with direct cytoplasmic localization data; a localization rather than core function.
Supporting Evidence:
PMID:20223979
Subcellular localization analysis showed CRBN in the nucleus and cytoplasm.
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
IMP
PMID:20223979
Identification of a primary target of thalidomide teratogeni...
ACCEPT
Summary: CRBN, as the substrate receptor of CRL4(CRBN), directs substrates for ubiquitin-dependent proteasomal degradation; a core process.
Reason: Directly supported by experimental evidence; central to CRBN function.
Supporting Evidence:
PMID:20223979
CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks.
GO:0031464 Cul4A-RING E3 ubiquitin ligase complex
IDA
PMID:20223979
Identification of a primary target of thalidomide teratogeni...
ACCEPT
Summary: CRBN was directly shown to form a DCX/CRL4 complex with DDB1, RBX1 and CUL4A.
Reason: Core complex membership supported by direct experimental identification of the DCX complex.
Supporting Evidence:
PMID:20223979
CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A.
GO:0005515 protein binding
IPI
PMID:20223979
Identification of a primary target of thalidomide teratogeni...
MARK AS OVER ANNOTATED
Summary: Protein-binding annotation capturing the direct CRBN-DDB1 interaction that incorporates CRBN into the CRL4 complex.
Reason: The DDB1 interaction is biologically central but the generic protein binding term is uninformative; complex membership is already captured by the Cul4-RING complex annotations, and the adaptor MF is better represented by the proposed substrate-adaptor term.
Supporting Evidence:
PMID:20223979
CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A.
GO:0005634 nucleus
IDA
PMID:20223979
Identification of a primary target of thalidomide teratogeni...
ACCEPT
Summary: Direct immunolocalization places CRBN in the nucleus.
Reason: Experimentally supported localization (IDA); a location rather than the core function.
Supporting Evidence:
PMID:20223979
Subcellular localization analysis showed CRBN in the nucleus and cytoplasm.
GO:0005737 cytoplasm
IDA
PMID:20223979
Identification of a primary target of thalidomide teratogeni...
ACCEPT
Summary: Direct immunolocalization places CRBN in the cytoplasm; CRBN acts in both the nucleus and cytoplasm, consistent with substrate degradation in both compartments.
Reason: Experimentally supported localization (IDA); a location rather than the core function. The dual nucleus/cytoplasm distribution is further corroborated by the falcon deep research synthesis.
Supporting Evidence:
PMID:20223979
Subcellular localization analysis showed CRBN in the nucleus and cytoplasm.
file:human/CRBN/CRBN-deep-research-falcon.md
Cereblon is localized in both the nucleus and cytoplasm, enabling it to ubiquitinate and degrade substrates in multiple cellular compartments
GO:0016567 protein ubiquitination
IMP
PMID:20223979
Identification of a primary target of thalidomide teratogeni...
ACCEPT
Summary: CRBN mediates ubiquitination of target proteins as the substrate receptor of CRL4(CRBN); a core process.
Reason: Directly supported by experimental evidence (IMP) and central to CRBN function.
Supporting Evidence:
PMID:20223979
CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks.
GO:1990756 ubiquitin-like ligase-substrate adaptor activity
IDA
PMID:26909574
Structural basis of lenalidomide-induced CK1ฮฑ degradation by...
NEW
Summary: CRBN is the substrate receptor/adaptor of the CRL4(CRBN) E3 ubiquitin ligase, recruiting substrates (and drug-induced neosubstrates) for ubiquitination. It has no intrinsic catalytic activity but confers substrate specificity to the complex.
Reason: The existing GOA set lacks any molecular function term for CRBN's actual role. GO:1990756 ubiquitin-like ligase-substrate adaptor activity is the precise, well-supported MF and is proposed as a new annotation. The substrate-adaptor (non-catalytic) nature is corroborated by the falcon deep research synthesis.
Supporting Evidence:
PMID:26909574
IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4(CRBN)) E3 ubiquitin ligase.
file:human/CRBN/CRBN-deep-research-falcon.md
CRBN does not possess enzymatic activity itself but rather acts as an adapter protein that confers substrate specificity to the ubiquitination machinery

Core Functions

CRBN is the substrate-recognition subunit of the CRL4(CRBN) cullin-RING E3 ubiquitin ligase, binding DDB1 through its N-terminal Lon-like domain and recruiting substrate proteins through its C-terminal CULT (thalidomide-binding) domain to direct their ubiquitination and proteasomal degradation.

Supporting Evidence:
  • PMID:20223979
    CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A.
  • PMID:26909574
    IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4(CRBN)) E3 ubiquitin ligase.

CRBN binds thalidomide-class drugs (thalidomide, lenalidomide, pomalidomide) and molecular-glue/PROTAC degraders in its CULT domain; drug binding acts as a molecular glue that reprograms CRBN substrate specificity to recruit neosubstrates (e.g. IKZF1, IKZF3, CK1alpha) for degradation. This neosubstrate recruitment is drug-induced rather than an endogenous function.

Supporting Evidence:
  • PMID:25108355
    These drugs directly bind Cereblon (CRBN) and promote the recruitment of substrates Ikaros (IKZF1) and Aiolos (IKZF3) to the E3 complex, thus leading to substrate ubiquitination and degradation.
  • PMID:26909574
    IMiDs also repurpose the ligase to target new proteins for degradation.

References

Annotation inferences using phylogenetic trees
Gene Ontology annotation based on UniPathway vocabulary mapping
Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location vocabulary mapping, accompanied by conservative changes to GO terms applied by UniProt
Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara
Identification of a primary target of thalidomide teratogenicity.
  • CRBN forms a CRL4 E3 ubiquitin ligase with DDB1 and Cul4A required for limb outgrowth and FGF8 expression; thalidomide binds CRBN and inhibits this ligase activity.
    "CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks."
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
  • The Cul4-Rbx1-DDB1-Cereblon E3 ubiquitin ligase is the target of IMiDs, which bind CRBN and promote recruitment of IKZF1/IKZF3 for ubiquitination and degradation.
    "These drugs directly bind Cereblon (CRBN) and promote the recruitment of substrates Ikaros (IKZF1) and Aiolos (IKZF3) to the E3 complex, thus leading to substrate ubiquitination and degradation."
A proteome-scale map of the human interactome network.
Lenalidomide induces ubiquitination and degradation of CK1ฮฑ in del(5q) MDS.
  • Lenalidomide induces CRL4(CRBN)-dependent, proteasome- and cullin-dependent ubiquitination and degradation of CK1alpha.
    "Lenalidomide induces the ubiquitination of casein kinase 1A1 (CK1alpha) by the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4(CRBN)), resulting in CK1alpha degradation."
Structural basis of lenalidomide-induced CK1ฮฑ degradation by the CRL4(CRBN) ubiquitin ligase.
  • CRBN is the substrate receptor of CRL4(CRBN); CK1alpha binding is strictly IMiD-dependent, illustrating drug-induced neosubstrate recruitment.
    "We show that CK1alpha binding to CRL4(CRBN) is strictly dependent on the presence of an IMiD."
Extensive disruption of protein interactions by genetic variants across the allele frequency spectrum in human populations.
A reference map of the human binary protein interactome.
Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.
The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
  • CRBN mediates Wnt-induced, IMiD-independent degradation of CK1alpha and is required for physiological Wnt signaling.
    "Wnt promotes the CRBN-dependent degradation of a subset of proteins. These substrates include Casein kinase 1alpha (CK1alpha), a negative regulator of Wnt signaling."
OpenCell: Endogenous tagging for the cartography of human cellular organization.
Reactome:R-HSA-9681169
CRBN binds IMiDs
file:human/CRBN/CRBN-deep-research-falcon.md
Falcon deep research report for CRBN
  • CRBN is a non-catalytic substrate-recognition adaptor of the CRL4(CRBN) E3 ubiquitin ligase that confers substrate specificity to the ubiquitination machinery.
    "CRBN does not possess enzymatic activity itself but rather acts as an adapter protein that confers substrate specificity to the ubiquitination machinery"

Suggested Questions for Experts

Q: Beyond MEIS2, GLUL and ILF2, what is the full endogenous (IMiD-independent) substrate repertoire of human CRL4(CRBN), and which degrons does CRBN recognize natively?

Suggested experts: Handa H, Ebert BL

Q: Is CRBN's regulation of BK/KCNT1 channels mediated by ubiquitination of a channel-associated substrate, or by a non-degradative scaffolding mechanism?

Suggested experts: Choi SY, Park CS

Suggested Experiments

Experiment: Perform global diGly (K-epsilon-GG) ubiquitinome and quantitative proteomics comparing CRBN-knockout and wild-type human cells in the absence of any IMiD, to define drug-independent CRL4(CRBN) substrates.

Hypothesis: CRBN has a defined set of endogenous neosubstrate-independent substrates whose stabilization explains the developmental phenotypes seen on CRBN loss.

Type: ubiquitinome and degradation proteomics

Experiment: Compare BK/KCNT1 channel surface expression and current in neurons expressing wild-type CRBN, a DDB1-binding-deficient mutant, and a ligase-dead CRL4 context, using surface biotinylation and electrophysiology.

Hypothesis: CRBN regulates BK channel surface expression through the CRL4 ubiquitin ligase activity rather than a degradation-independent scaffold function.

Type: electrophysiology and surface-expression assay

Deep Research

Falcon

(CRBN-deep-research-falcon.md)
Comprehensive Research Report: Cereblon (CRBN) - Functional Annotation Falcon Edison Scientific Literature 21 citations 1 artifacts 2026-06-20T07:01:03.923571

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: Cereblon (CRBN) - Functional Annotation

Gene Identity and Overview

Cereblon (CRBN, UniProt accession Q96SW2) is a highly conserved human protein that functions as the substrate receptor subunit of the Cullin-RING E3 ubiquitin ligase 4 (CRL4^CRBN) complex (kroupova2024designofa pages 1-3, cieslak2023cereblonrecruitingprotacswill pages 1-3, ito2021exploitingubiquitinligase pages 2-4). The gene encodes a 441-442 amino acid protein belonging to the CRBN family, with key domains including CULT, Lon protease N-terminal, and Yippee/Mis18/Cereblon domains, consistent with the UniProt annotation provided (ito2020molecularmechanismsof pages 2-4). CRBN came to prominence in 2010 when it was identified as the direct molecular target of thalidomide using affinity purification with ferrite glycidyl methacrylate (FG) beads, a discovery that revolutionized our understanding of both the teratogenic and therapeutic effects of thalidomide-class drugs (ito2020molecularmechanismsof pages 2-4).

Primary Molecular Function

Substrate Receptor in E3 Ubiquitin Ligase Complex

The primary function of cereblon is to serve as a substrate receptor within the multi-subunit CRL4^CRBN E3 ubiquitin ligase complex (cieslak2023cereblonrecruitingprotacswill pages 1-3, merinocacho2025cullinringligasebioe3 pages 1-2, ito2021exploitingubiquitinligase pages 2-4). Unlike catalytic enzymes, CRBN does not possess enzymatic activity itself but rather acts as an adapter protein that confers substrate specificity to the ubiquitination machinery (watson2022moleculargluecelmoda pages 1-3). The complete CRL4^CRBN complex consists of four core components: RBX1/ROC1 (RING-box protein 1), CUL4A or CUL4B (Cullin-4), DDB1 (DNA damage-binding protein 1), and CRBN as the substrate receptor (cieslak2023cereblonrecruitingprotacswill pages 1-3, ito2020molecularmechanismsof pages 2-4).

In this complex, RBX1 recruits E2 ubiquitin-conjugating enzymes, CUL4 provides the scaffold, DDB1 serves as an adaptor linking CRBN to the catalytic core, and CRBN directly recognizes and binds substrate proteins, positioning them for ubiquitination and subsequent proteasomal degradation (ito2021exploitingubiquitinligase pages 2-4, ito2020molecularmechanismsof pages 2-4). Two E2 enzymes, UBE2D3 and UBE2G1, have been identified through CRISPR screening as cooperatively functioning upstream of CRL4^CRBN, with UBE2D3 involved in monoubiquitination and UBE2G1 extending polyubiquitin chains (ito2021exploitingubiquitinligase pages 2-4).

Structural Architecture and Conformational Dynamics

CRBN contains three folded domains that are critical for its function (kroupova2024designofa pages 1-3, watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3):

  1. Lon protease-like domain (Lon domain): Located at the N-terminus, this domain participates in substrate recognition and contributes to the conformational rearrangement critical for drug-induced neosubstrate binding (watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3).

  2. Helical bundle (HB): This intermedial domain docks into a central hydrophobic cleft formed at the interface of DDB1's BPA and BPC ฮฒ-propeller domains, mediating the interaction between CRBN and the adaptor protein DDB1 (watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3).

  3. Thalidomide-binding domain (TBD): The C-terminal domain contains the drug-binding pocket where immunomodulatory drugs (IMiDs) and cereblon E3 ligase modulators (CELMoDs) bind (kroupova2024designofa pages 1-3, watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3).

A critical recent discovery is that CRBN exists in dynamic equilibrium between "open" and "closed" conformational states (watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3). In the open conformation, the Lon domain and TBD are separated at approximately a 45-degree angle relative to one another. Binding of CELMoD compounds to the TBD is necessary and sufficient to trigger allosteric rearrangement from the open to the closed conformation, where the Lon and TBD domains tightly interact (watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3). This conformational change is essential for stable neosubstrate association, as neosubstrates like Ikaros only stably bind to the closed CRBN conformation (watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3). An N-terminal belt (residues 48-63) becomes ordered during closure, extending from the Lon domain to truss the TBD and support the closed state (watson2022moleculargluecelmod pages 1-2).

Substrate Recognition Mechanism

CRBN recognizes substrates through specific structural motifs, most notably the G-loop degron (oleinikovas2024fromthalidomideto pages 2-4). The G-loop is an eight-amino-acid stretch characterized by an invariant glycine at the sixth position (designated as position G), with flanking residues designated G-5 through G+2 (oleinikovas2024fromthalidomideto pages 2-4). This motif typically forms an alpha-turn or beta-hairpin structure that enables key molecular interactions:

  • Backbone hydrogen bonds: Three backbone carbonyl groups at positions G-3, G-2, and G-1 form hydrogen bonds with CRBN residues Asn351, His357, and Trp400, respectively (oleinikovas2024fromthalidomideto pages 2-4).
  • van der Waals contacts: The invariant glycine and surrounding residues at positions G-4, G-3, G-2, and G+1 engage in favorable van der Waals interactions with CRBN (oleinikovas2024fromthalidomideto pages 2-4).

Deep mutational scanning studies have confirmed that CRBN residues involved in these hydrogen bonds (particularly N351, H357, W400) are critical hot spots for mutation-acquired resistance to molecular glue degraders (oleinikovas2024fromthalidomideto pages 2-4). However, recent research has identified non-canonical degron motifs beyond the G-loop, such as the RT-loop (RDxS motif) in VAV1, expanding our understanding of CRBN substrate recognition diversity (oleinikovas2024fromthalidomideto pages 2-4).

Substrate Specificity

Endogenous Substrates

Under physiological conditions, CRBN recognizes several endogenous substrates, although the complete native substrate repertoire remains an active area of investigation (ito2021exploitingubiquitinligase pages 2-4):

  1. MEIS2 (Meis homeobox 2): Identified as an endogenous substrate of CRL4^CRBN (costacurta2021molecularmechanismsof pages 2-4, ito2021exploitingubiquitinligase pages 2-4).

  2. SLO1 (KCNMA1): A calcium-activated potassium channel that represents another native CRBN substrate (ito2021exploitingubiquitinligase pages 2-4).

  3. ILF2 (Interleukin enhancer-binding factor 2): A DNA and RNA-binding protein identified through quantitative proteomics using stable isotope labeling by amino acids in cell culture (SILAC). CRBN promotes the ubiquitination and proteasomal degradation of ILF2, with lysine 45 (K45) identified as a key ubiquitination site (lian2020cereblonpromotesthe pages 1-2).

Endogenous substrates may contain cyclic imide structures arising from intramolecular cyclization of glutamine or asparagine residues, which are chemically reminiscent of IMiDs and could drive physiological protein degradation (oleinikovas2024fromthalidomideto pages 2-4).

Drug-Induced Neosubstrates

A defining feature of CRBN is its capacity to recognize "neosubstrates" - proteins that are recruited for degradation only in the presence of specific small-molecule ligands (costacurta2021molecularmechanismsof pages 2-4, ito2021exploitingubiquitinligase pages 2-4, ito2020molecularmechanismsof pages 2-4). This drug-induced change in substrate specificity forms the molecular basis for the therapeutic and adverse effects of thalidomide and its derivatives:

Classical IMiD-induced neosubstrates:

  1. IKZF1 (Ikaros) and IKZF3 (Aiolos): Transcription factors of the Ikaros family that are degraded in the presence of lenalidomide and pomalidomide. These were identified in 2014 through quantitative proteomics and genetic screening approaches (costacurta2021molecularmechanismsof pages 2-4, ito2021exploitingubiquitinligase pages 2-4). IKZF1/3 degradation is central to the anti-myeloma activity of IMiDs, as these proteins sustain expression of IRF4 and MYC, which are critical for myeloma cell survival (costacurta2021molecularmechanismsof pages 2-4).

  2. CK1ฮฑ (Casein kinase 1 alpha): Targeted for degradation by lenalidomide specifically in myelodysplastic syndrome with del(5q), where haploinsufficiency of CK1ฮฑ sensitizes cells to apoptosis via p53 stabilization (costacurta2021molecularmechanismsof pages 2-4).

  3. GSPT1 (G1-to-S phase transition 1): A translation termination factor degraded by compounds such as CC-885 and CC-90009, with implications for viral infection treatment (oleinikovas2024fromthalidomideto pages 2-4).

  4. SALL4 (Spalt-like transcription factor 4): A key mediator of thalidomide teratogenicity. SALL4 degradation disrupts limb development, explaining the birth defects historically associated with thalidomide exposure (costacurta2021molecularmechanismsof pages 2-4, oleinikovas2024fromthalidomideto pages 2-4).

Recently identified neosubstrates (2024-2025):

  1. G3BP2 (Ras-GTPase-activating protein SH3 domain-binding protein 2): Identified through high-throughput proteomics as a cereblon neosubstrate using molecular surface mimicry, without containing a classical G-loop degron (oleinikovas2024fromthalidomideto pages 2-4).

  2. KDM4B, VCL (Vinculin): Additional novel neosubstrates identified through comprehensive screening platforms (oleinikovas2024fromthalidomideto pages 2-4).

  3. VAV1: A hematopoietic-specific signaling protein degraded via an RT-loop degron (RDxS motif at residues 796-799), representing a non-canonical recognition mechanism distinct from the G-loop (oleinikovas2024fromthalidomideto pages 2-4).

Over 2,500 proteins in the human proteome contain potential G-loop motifs and could theoretically be targeted by rationally designed CRBN-based molecular glues (oleinikovas2024fromthalidomideto pages 2-4).

Subcellular Localization

Cereblon is localized in both the nucleus and cytoplasm, enabling it to ubiquitinate and degrade substrates in multiple cellular compartments (kaji2020characterizationofcereblondependent pages 1-2, lian2020cereblonpromotesthe pages 1-2). Studies using TurboID proximity labeling with nuclear-localized CRBN (CRBN-Flag-NLS-TurboID) and cytoplasmic-localized constructs have demonstrated that CRBN functions in both compartments (lian2020cereblonpromotesthe pages 1-2).

Visualization studies using the Fluoppi system to detect ternary complex formation have shown that CRBN-recruiting degraders form complexes in subcellular locations corresponding to their target protein localization. For example, BRD4-targeting degraders form ternary complexes mainly in the nucleus, while FKBP12-targeting degraders form complexes in the cytoplasm, demonstrating that CRBN utilizes the proteasome to degrade target proteins in their corresponding localized regions (kaji2020characterizationofcereblondependent pages 1-2).

Biological Pathways and Processes

Transcriptional Regulation

CRBN plays a critical role in regulating hematopoietic transcriptional programs through degradation of IKZF1 and IKZF3 (costacurta2021molecularmechanismsof pages 2-4). These transcription factors form part of a core regulatory network in B cells and plasma cells, where they:

  • Sustain expression of IRF4 (interferon regulatory factor 4), an "oncogene of addiction" in multiple myeloma
  • Support MYC transcription, with IRF4 and MYC forming a positive feedback loop
  • Suppress IL-2 gene transcription; their degradation leads to IL-2 production and T-cell costimulation (costacurta2021molecularmechanismsof pages 2-4)

Cell Cycle Regulation

IMiD-induced CRBN activity affects cell cycle progression through multiple mechanisms. Treatment with IMiDs causes G0-G1 cell cycle arrest by inducing tumor suppressors p21 and p27, increasing expression of Early Growth Response (EGR) protein family members, and inhibiting cyclin-dependent kinases 2, 4, and 6 (costacurta2021molecularmechanismsof pages 2-4).

Developmental Processes

CRBN's role in development is most dramatically illustrated by thalidomide teratogenicity. Drug binding to CRBN leads to degradation of SALL4, a transcription factor essential for limb development, as well as p63 (tumor protein p63), disrupting normal developmental programs in embryos (costacurta2021molecularmechanismsof pages 2-4, ito2020molecularmechanismsof pages 2-4). Expression of thalidomide-binding-deficient CRBN mutants (such as Y384A/W386A) in zebrafish and chicken embryos confers resistance to thalidomide-induced developmental defects, confirming CRBN as the primary target for teratogenicity (ito2020molecularmechanismsof pages 2-4).

Protein Homeostasis

As part of the ubiquitin-proteasome system, CRBN contributes to cellular protein quality control by marking specific substrates for degradation. For instance, CRBN promotes the ubiquitination and degradation of ILF2, a protein involved in gene expression regulation and highly expressed in multiple tumor tissues (lian2020cereblonpromotesthe pages 1-2).

Therapeutic Relevance and Clinical Applications

IMiD Drugs and Clinical Use

Cereblon is the direct molecular target of immunomodulatory imide drugs (IMiDs), including thalidomide, lenalidomide (Revlimid), and pomalidomide (Pomalyst) (cieslak2023cereblonrecruitingprotacswill pages 1-3, costacurta2021molecularmechanismsof pages 2-4, ito2021exploitingubiquitinligase pages 2-4, ito2020molecularmechanismsof pages 2-4). These drugs have FDA approval for:

  • Multiple myeloma: Lenalidomide is a first-line therapy, often used in combination with proteasome inhibitors and monoclonal antibodies
  • Myelodysplastic syndrome with del(5q): Lenalidomide specifically targets CK1ฮฑ
  • Mantle cell lymphoma and follicular lymphoma: Lenalidomide shows efficacy in these B-cell malignancies (ito2021exploitingubiquitinligase pages 2-4, ito2020molecularmechanismsof pages 2-4)

As of 2023, twelve out of fifteen PROTACs in clinical trials recruit CRBN as the E3 ligase, highlighting its dominant position in targeted protein degradation therapeutics (cieslak2023cereblonrecruitingprotacswill pages 1-3).

Next-Generation CELMoDs

Next-generation cereblon E3 ligase modulators (CELMoDs) such as mezigdomide (CC-92480) and iberdomide (CC-220) have been developed with enhanced potency for CRBN binding and neosubstrate degradation (watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3). These compounds show:

  • Greater cereblon-binding affinity than classical IMiDs
  • More potent degradation of IKZF1 and IKZF3
  • Activity in lenalidomide/pomalidomide-resistant multiple myeloma, including triple-class and penta-refractory disease (watson2022moleculargluecelmoda pages 1-3)

The improved efficacy of CELMoDs has been linked to their superior ability to induce the closed CRBN conformation, thereby more efficiently activating the E3 ligase complex for neosubstrate recruitment (watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3).

Drug Resistance Mechanisms

Resistance to IMiD therapy in multiple myeloma and other cancers can arise through several CRBN-related mechanisms (cieslak2023cereblonrecruitingprotacswill pages 1-3, costacurta2021molecularmechanismsof pages 2-4):

  1. CRBN downregulation: Reduced expression due to gene deletion or epigenetic silencing
  2. CRBN mutations: Missense mutations, particularly in the thalidomide-binding domain, can impair drug binding while maintaining some native function
  3. Splice variants: Exclusion of exon 10 (encoding part of the TBD) produces non-functional CRBN isoforms
  4. Copy number loss: Hemizygous or homozygous deletion of the CRBN locus

Deep sequencing has revealed that CRBN aberrations significantly reduce survival in multiple myeloma patients treated with IMiDs (costacurta2021molecularmechanismsof pages 2-4). Recent structural biology analyses suggest that certain CRBN mutations may be overcome by more potent CELMoDs that can still induce conformational closure and neosubstrate recruitment despite the mutations (watson2022moleculargluecelmoda pages 1-3).

Recent Research Developments (2023-2026)

Conformational Dynamics and Allostery

Major advances in 2022-2024 using cryo-electron microscopy have revealed that CRBN exists in dynamic equilibrium between open and closed states (watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3). Watson et al. demonstrated that CELMoD compound binding to the TBD is both necessary and sufficient to trigger the allosteric rearrangement from open to closed conformation, and that neosubstrates only stably associate with the closed form (watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3). This mechanistic insight has profound implications for drug design, as compounds that more efficiently promote closure tend to be more efficacious degraders.

Advanced Structural Tools

In 2024, Kroupova et al. developed CRBNmidi, a novel construct that expresses from E. coli with high yields as soluble, stable protein without requiring co-expression with DDB1 (kroupova2024designofa pages 1-3). This construct has been benchmarked for wild-type functionality and enables high-resolution crystallographic and biophysical studies of CRBN-degrader complexes, accelerating structure-based drug discovery.

Expanded Neosubstrate Landscape

High-throughput proteomics platforms deployed in 2024-2025 have dramatically expanded the known CRBN neosubstrate landscape (oleinikovas2024fromthalidomideto pages 2-4):

  • Rankovic et al. (2025) processed 100 CRBN ligands across two cancer cell lines using data-independent acquisition mass spectrometry, identifying 50 novel neosubstrates including KDM4B, G3BP2, and VCL, many lacking classical G-loop motifs
  • Annunziato et al. (2026) characterized G3BP2 degradation via molecular surface mimicry, revealing new principles of CRBN-neosubstrate engagement
  • Lin et al. (2025) discovered that VAV1 uses a non-canonical RT-loop degron (RDxS motif) for CRBN-mediated degradation

Context-Dependent Interactomes

The ProxiCapture method developed by Kazi et al. (2026) combines purified CRBN with native cell or tissue lysates to map context-dependent neosubstrate profiles across different cell types, maturation states, and tissues. This work revealed that degrader-dependent interactors of CRBN are highly context-dependent, requiring broad sampling to uncover the full "glueable" proteome (oleinikovas2024fromthalidomideto pages 2-4).

Mechanistic Insights into Degrader Action

O'Connor et al. (2025) demonstrated that tuning the open-close equilibrium of CRBN with different small molecules directly influences protein degradation efficacy, identifying key residues in the ligand-binding pocket and N-terminal belt essential for closure. Compounds that cannot induce CRBN closure have greatly reduced probability of yielding active degrader molecules (kroupova2024designofa pages 1-3).

Aspect Summary Key details / examples Evidence
Gene/protein identity CRBN (cereblon), UniProt Q96SW2, human is the substrate receptor of the CRL4^CRBN E3 ubiquitin ligase complex CRBN associates with DDB1, CUL4A/4B, and RBX1/ROC1 to confer substrate specificity for ubiquitination and subsequent proteasomal degradation (cieslak2023cereblonrecruitingprotacswill pages 1-3, merinocacho2025cullinringligasebioe3 pages 1-2, ito2021exploitingubiquitinligase pages 2-4, watson2022moleculargluecelmoda pages 1-3)
Primary molecular function Substrate recognition adaptor/receptor in a Cullin-RING ligase, rather than a catalytic enzyme itself CRBN recruits substrates to the CRL4 core, enabling E2-dependent ubiquitin transfer; drug binding can reprogram substrate specificity toward neosubstrates (cieslak2023cereblonrecruitingprotacswill pages 1-3, ito2021exploitingubiquitinligase pages 2-4, watson2022moleculargluecelmoda pages 1-3, ito2020molecularmechanismsof pages 2-4)
Structural organization CRBN contains three folded domains plus an N-terminal region important for conformational control Lon protease-like domain (Lon), helical bundle (HB) that docks to DDB1, and C-terminal thalidomide-binding domain (TBD) harboring the ligand pocket; ligand binding promotes open-to-closed rearrangement (kroupova2024designofa pages 1-3, watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3)
Conformational mechanism Small-molecule binding regulates CRBN conformation and thereby substrate recruitment CELMoD/IMiD binding to the TBD is sufficient to trigger transition from an open to closed CRBN state; stable neosubstrate engagement requires the closed state (watson2022moleculargluecelmod pages 1-2, watson2022moleculargluecelmoda pages 1-3)
Endogenous substrate recognition CRBN recognizes native cellular substrates in the absence of exogenous drugs, although the endogenous substrate landscape is still being defined Reviews summarize MEIS2 and SLO1 as endogenous CRL4^CRBN substrates; experimental work identified ILF2 as a CRBN-interacting substrate whose ubiquitination and proteasomal degradation are promoted by CRBN (ito2021exploitingubiquitinligase pages 2-4, lian2020cereblonpromotesthe pages 1-2)
Endogenous substrates highlighted in this report Representative native targets linked to physiological CRBN activity MEIS2; SLO1; ILF2 (with ILF2 K45 implicated as a key ubiquitination site in one study) (ito2021exploitingubiquitinligase pages 2-4, lian2020cereblonpromotesthe pages 1-2)
Drug-induced neosubstrates IMiDs/CELMoDs convert CRBN into a recruiter of neosubstrates that are not normally targeted in the same way Canonical examples include IKZF1 (Ikaros) and IKZF3 (Aiolos); additional therapeutically or biologically important neosubstrates include CK1ฮฑ, GSPT1, and teratogenicity-linked SALL4 (costacurta2021molecularmechanismsof pages 2-4, ito2021exploitingubiquitinligase pages 2-4, oleinikovas2024fromthalidomideto pages 2-4, ito2020molecularmechanismsof pages 2-4)
Degron / binding principles Many CRBN molecular-glue neosubstrates use a recognizable structural motif Structural analyses describe a G-loop motif whose backbone and side chains contact CRBN residues such as N351, H357, and W400 in drug-stabilized ternary complexes; this explains selectivity rules for many neosubstrates (oleinikovas2024fromthalidomideto pages 2-4)
Subcellular localization CRBN functions in both nucleus and cytoplasm Prior work summarized in later studies notes CRBN localization in both compartments; ternary complex imaging showed CRBN-based degraders can operate mainly in the nucleus for BRD4-directed degradation and in the cytoplasm for FKBP12-directed degradation (kaji2020characterizationofcereblondependent pages 1-2, lian2020cereblonpromotesthe pages 1-2)
Role in IMiD mechanism CRBN is the direct target of thalidomide-class drugs and the central mediator of their downstream effects Thalidomide/lenalidomide/pomalidomide bind the TBD; this rewires CRBN substrate specificity, causing ubiquitination and degradation of selected neosubstrates and explaining major therapeutic as well as teratogenic effects (kroupova2024designofa pages 1-3, costacurta2021molecularmechanismsof pages 2-4, ito2021exploitingubiquitinligase pages 2-4, ito2020molecularmechanismsof pages 2-4)
Therapeutic relevance CRBN is a major E3 ligase co-opted in modern targeted protein degradation A large fraction of clinical PROTACs/degraders recruit CRBN; next-generation CELMoDs such as mezigdomide exploit improved CRBN engagement and neosubstrate degradation potency (cieslak2023cereblonrecruitingprotacswill pages 1-3, watson2022moleculargluecelmoda pages 1-3)

Table: This table summarizes the core functional annotation of human cereblon (CRBN), including its structural domains, molecular role in CRL4 ubiquitin ligase complexes, key endogenous and drug-induced substrates, localization, and importance in IMiD pharmacology. It is useful as a compact evidence-backed reference for the main biological and translational features of CRBN.

Summary and Conclusions

Cereblon (CRBN, UniProt Q96SW2) functions as the substrate receptor of the CRL4^CRBN E3 ubiquitin ligase complex, where it confers substrate specificity for targeted protein degradation. The protein contains three key domainsโ€”Lon, helical bundle, and thalidomide-binding domainโ€”that undergo dynamic conformational rearrangement between open and closed states upon ligand binding. This conformational change is critical for stable neosubstrate recruitment and subsequent ubiquitination.

CRBN recognizes both endogenous substrates (MEIS2, SLO1, ILF2) and, when bound to small-molecule ligands, drug-induced neosubstrates (IKZF1/3, CK1ฮฑ, GSPT1, SALL4). The G-loop degron motif is a primary recognition element, though non-canonical degrons have recently been identified. The protein localizes to both nucleus and cytoplasm, enabling substrate degradation in multiple cellular compartments.

As the direct target of thalidomide and related IMiDs, CRBN mediates both the therapeutic effects (via IKZF1/3 degradation in hematological malignancies) and adverse effects (via SALL4 degradation causing teratogenicity) of these drugs. CRBN is currently the most widely recruited E3 ligase in clinical-stage targeted protein degradation therapeutics, with next-generation CELMoDs and numerous PROTACs in development or clinical trials.

Recent advances (2023-2026) have revealed the importance of conformational dynamics in degrader function, expanded the neosubstrate landscape to include non-canonical degron-containing proteins, and developed new tools (CRBNmidi construct, ProxiCapture) for studying CRBN biology. These discoveries provide a foundation for rational design of more effective and selective CRBN-based therapeutics for cancer and other diseases.

References

  1. (kroupova2024designofa pages 1-3): Alena Kroupova, Valentina A. Spiteri, Hirotake Furihata, Darren Darren, Sarath Ramachandran, Zoe J. Rutter, Sohini Chakraborti, Kevin Haubrich, Julie Pethe, Denzel Gonzales, Andre Wijaya, Maria Rodriguez-Rios, Dylan M. Lynch, William Farnaby, Mark A. Nakasone, David Zollman, and Alessio Ciulli. Design of a cereblon construct for crystallographic and biophysical studies of protein degraders. BioRxiv, Jan 2024. URL: https://doi.org/10.1101/2024.01.17.575503, doi:10.1101/2024.01.17.575503. This article has 48 citations.

  2. (cieslak2023cereblonrecruitingprotacswill pages 1-3): Marcin Cieล›lak and Marta Sล‚owianek. Cereblon-recruiting protacs: will new drugs have to face old challenges? Pharmaceutics, 15:812, Mar 2023. URL: https://doi.org/10.3390/pharmaceutics15030812, doi:10.3390/pharmaceutics15030812. This article has 45 citations.

  3. (ito2021exploitingubiquitinligase pages 2-4): Takumi Ito, Yuki Yamaguchi, and Hiroshi Handa. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology. Cell Chemical Biology, 28:987-999, Jul 2021. URL: https://doi.org/10.1016/j.chembiol.2021.04.012, doi:10.1016/j.chembiol.2021.04.012. This article has 66 citations and is from a domain leading peer-reviewed journal.

  4. (ito2020molecularmechanismsof pages 2-4): Takumi ITO and Hiroshi HANDA. Molecular mechanisms of thalidomide and its derivatives. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 96:189-203, Jun 2020. URL: https://doi.org/10.2183/pjab.96.016, doi:10.2183/pjab.96.016. This article has 152 citations.

  5. (merinocacho2025cullinringligasebioe3 pages 1-2): Laura Merino-Cacho, Orhi Barroso-Gomila, Mรณnica Pozo-Rodrรญguez, Veronica Muratore, Claudia Guinea-Pรฉrez, รlvaro Serrano, Coralia Pรฉrez, Sandra Cano-Lรณpez, Ainhoa Urcullu, Mikel Azkargorta, Ibon Iloro, Carles Galdeano, Jordi Juรกrez-Jimรฉnez, Ugo Mayor, Felix Elortza, Rosa Barrio, and James D. Sutherland. Cullin-ring ligase bioe3 reveals molecular-glue-induced neosubstrates and rewiring of the endogenous cereblon ubiquitome. Cell Communication and Signaling, Feb 2025. URL: https://doi.org/10.1186/s12964-025-02091-5, doi:10.1186/s12964-025-02091-5. This article has 12 citations and is from a peer-reviewed journal.

  6. (watson2022moleculargluecelmoda pages 1-3): Edmond R. Watson, Scott Novick, Mary E. Matyskiela, Philip P. Chamberlain, Andres H. de la Peรฑa, Jinyi Zhu, Eileen Tran, Patrick R. Griffin, Ingrid E. Wertz, and Gabriel C. Lander. Molecular glue celmod compounds are regulators of cereblon conformation. Science, 378:549-553, Nov 2022. URL: https://doi.org/10.1126/science.add7574, doi:10.1126/science.add7574. This article has 203 citations and is from a highest quality peer-reviewed journal.

  7. (watson2022moleculargluecelmod pages 1-2): Edmond R. Watson, Scott J. Novick, Mary E. Matyskiela, Philip P. Chamberlain, Andres Hernandez de la Peรฑa, Jin-Yi Zhu, Eileen Tran, Patrick R. Griffin, Ingrid E. Wertz, and Gabriel C. Lander. Molecular glue celmod compounds are allosteric regulators of cereblon conformation. bioRxiv, Jul 2022. URL: https://doi.org/10.1101/2022.07.02.498551, doi:10.1101/2022.07.02.498551. This article has 2 citations.

  8. (oleinikovas2024fromthalidomideto pages 2-4): Vladas Oleinikovas, Pablo Gainza, Thomas Ryckmans, Bernhard Fasching, and Nicolas H. Thomรค. From thalidomide to rational molecular glue design for targeted protein degradation. Jan 2024. URL: https://doi.org/10.1146/annurev-pharmtox-022123-104147, doi:10.1146/annurev-pharmtox-022123-104147. This article has 175 citations and is from a highest quality peer-reviewed journal.

  9. (costacurta2021molecularmechanismsof pages 2-4): Matteo Costacurta, Jackson He, Philip E. Thompson, and Jake Shortt. Molecular mechanisms of cereblon-interacting small molecules in multiple myeloma therapy. Nov 2021. URL: https://doi.org/10.3390/jpm11111185, doi:10.3390/jpm11111185. This article has 31 citations.

  10. (lian2020cereblonpromotesthe pages 1-2): Qihui Lian, Yuan Gao, Qian Li, Xian He, Xiaogang Jiang, Zhongjian Pu, and Guoqiang Xu. Cereblon promotes the ubiquitination and proteasomal degradation of interleukin enhancer-binding factor 2. The Protein Journal, 39:411-421, Oct 2020. URL: https://doi.org/10.1007/s10930-020-09918-9, doi:10.1007/s10930-020-09918-9. This article has 7 citations.

  11. (kaji2020characterizationofcereblondependent pages 1-2): Tomohiro Kaji, Hiroshi Koga, Mutsumi Kuroha, Toshihiko Akimoto, and Kenji Hayata. Characterization of cereblon-dependent targeted protein degrader by visualizing the spatiotemporal ternary complex formation in cells. Scientific Reports, Feb 2020. URL: https://doi.org/10.1038/s41598-020-59966-5, doi:10.1038/s41598-020-59966-5. This article has 14 citations and is from a peer-reviewed journal.

Artifacts

Citations

  1. ito2020molecularmechanismsof pages 2-4
  2. watson2022moleculargluecelmoda pages 1-3
  3. ito2021exploitingubiquitinligase pages 2-4
  4. watson2022moleculargluecelmod pages 1-2
  5. oleinikovas2024fromthalidomideto pages 2-4
  6. lian2020cereblonpromotesthe pages 1-2
  7. costacurta2021molecularmechanismsof pages 2-4
  8. kaji2020characterizationofcereblondependent pages 1-2
  9. cieslak2023cereblonrecruitingprotacswill pages 1-3
  10. kroupova2024designofa pages 1-3
  11. https://doi.org/10.1101/2024.01.17.575503,
  12. https://doi.org/10.3390/pharmaceutics15030812,
  13. https://doi.org/10.1016/j.chembiol.2021.04.012,
  14. https://doi.org/10.2183/pjab.96.016,
  15. https://doi.org/10.1186/s12964-025-02091-5,
  16. https://doi.org/10.1126/science.add7574,
  17. https://doi.org/10.1101/2022.07.02.498551,
  18. https://doi.org/10.1146/annurev-pharmtox-022123-104147,
  19. https://doi.org/10.3390/jpm11111185,
  20. https://doi.org/10.1007/s10930-020-09918-9,
  21. https://doi.org/10.1038/s41598-020-59966-5,

๐Ÿ“š Additional Documentation

Notes

(CRBN-notes.md)

CRBN (Cereblon) โ€” Gene Review Notes

UniProt: Q96SW2 (CRBN_HUMAN), 442 aa. HGNC:30185. Gene on chromosome 3.

Summary of function

CRBN (cereblon) is the substrate-recognition (substrate-receptor) subunit of a CRL4
cullin-RING E3 ubiquitin ligase, the DCX/CRL4(CRBN) complex composed of DDB1, CUL4A or
CUL4B, RBX1 and CRBN. It recruits substrate proteins for ubiquitination and subsequent
proteasomal degradation [PMID:20223979, PMID:25108355, PMID:26909574]. Structurally it has
an N-terminal Lon-protease-like domain (no protease activity; the ATP-binding/catalytic
residues are absent โ€” UniProt CAUTION) and a C-terminal thalidomide-binding domain (CULT
domain) that coordinates a structural Zn2+ ion and binds thalidomide-class drugs. DDB1 is
bound via the N-terminal region PMID:25108355.

E3 ligase / substrate receptor role (core)

  • CRBN forms a DCX (DDB1-CUL4-X-box) / CRL4(CRBN) E3 ubiquitin ligase with DDB1, CUL4A and
    RBX1 PMID:20223979. ComplexPortal records both CUL4A (CPX-2759) and CUL4B
    (CPX-2762) variants (UniProt DR lines), supporting part_of both Cul4A-RING and Cul4B-RING
    E3 ubiquitin ligase complex.
  • The complex is "important for limb outgrowth and expression of the fibroblast growth
    factor Fgf8 in zebrafish and chicks" PMID:20223979. Thalidomide binding inhibits the
    associated ligase activity, the basis of teratogenicity PMID:20223979.
  • Endogenous substrates ubiquitinated/degraded by CRL4(CRBN) include MEIS2, GLUL (glutamine
    synthetase), ILF2 (UniProt FUNCTION summary; PMID:26990986, PMID:33009960). These support
    protein ubiquitination and proteasome-mediated ubiquitin-dependent protein catabolic
    process (involved_in).

IMiD / molecular-glue neosubstrate biology (drug-induced, not endogenous)

  • Thalidomide, lenalidomide, pomalidomide (IMiDs) bind the CRBN CULT/thalidomide-binding
    domain [PMID:25108355 "These drugs directly bind Cereblon (CRBN)"; binding residues
    His378/His380/Trp386, Zn at 323/326/391/394 from UniProt FT]. Drug binding reprograms
    ("molecular glue") substrate specificity to recruit neosubstrates such as IKZF1 (Ikaros),
    IKZF3 (Aiolos), and CK1ฮฑ (CSNK1A1) for ubiquitination/degradation
    [PMID:25108355; PMID:26131937 "lenalidomide induces the ubiquitination of casein kinase
    1A1 (CK1ฮฑ) by the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN"; PMID:26909574 "CK1ฮฑ binding
    to CRL4(CRBN) is strictly dependent on the presence of an IMiD"].
  • CK1ฮฑ and IKZF1 recruitment is STRICTLY IMiD-dependent PMID:26909574 โ€” so neosubstrate
    recruitment is a pharmacological gain-of-function, not the endogenous function. Provenance
    for the molecular-glue mechanism is the IMiD literature; endogenous human substrate
    capture is sparse.
  • The CK1ฮฑ/CSNK1A1 IPI interaction in GOA (PMID:26131937, PMID:26909574) is the
    IMiD-induced (lenalidomide) drug-bound interaction.

Wnt signaling

  • PMID:34489457 reports that Wnt promotes CRBN-dependent degradation of CK1ฮฑ (a negative
    regulator of Wnt) in an IMiD-INDEPENDENT manner; CRBN is required for physiological Wnt
    signaling, and modulation in zebrafish and Drosophila yields Wnt phenotypes
    PMID:34489457. This supports positive regulation
    of Wnt signaling pathway (IMP, source FlyBase). The IBA transfer to the same term derives
    from the same lineage of evidence (fly FBgn0037780). Reasonable to keep as a non-core
    regulatory process.

Ion-channel / neuronal roles (endogenous, mostly non-core, largely from rodent orthologs)

  • CRBN negatively regulates the large-conductance Ca2+-activated K+ (BK) channel via
    interaction with KCNT1, maintaining presynaptic glutamate release, memory and learning
    [UniProt FUNCTION; PMID:18414909; PMID:29530986]. The MRT2 p.R419X truncation dysregulates
    BK channel expression. These underlie the IEA-by-orthology terms transmembrane transporter
    binding (GO:0044325), negative regulation of monoatomic ion transmembrane transport
    (GO:0034766), and the behavior terms (locomotory exploration behavior GO:0035641) โ€” all
    transferred from rat (Q56AP7) or mouse (Q8C7D2) orthologs. Endogenous but peripheral to
    the core E3-adaptor function; keep as non-core where literature supports, mark broad
    ortholog transfers as over-annotation where weak.

Subcellular location

  • Cytoplasm and nucleus [PMID:20223979, IDA]. Also peripheral membrane protein (by
    similarity), consistent with membrane/perinuclear IEA. Cytosol TAS from Reactome
    (R-HSA-9681169, "CRBN binds IMiDs").

Disease

  • Autosomal recessive intellectual developmental disorder 2 (MRT2); variants p.R419X
    (truncation) and C391R [PMID:15557513, PMID:28143899]. CRBN is highly expressed in brain.

Interactome / protein binding annotations

  • Multiple GO:0005515 "protein binding" IPI annotations come from high-throughput
    binary/affinity interactome screens: PMID:25416956 (HuRI/Rolland โ€” RBPMS, PAK5),
    PMID:31515488 (Fragoza โ€” PAK5), PMID:32296183 (HuRI/Luck โ€” MISP), PMID:32814053 (Haenig โ€”
    KLF11, COL26A1), PMID:35271311 (OpenCell โ€” DDB1). These are generic "protein binding"
    with no specific informative MF; per curation guidance, bare protein binding should be
    marked as over-annotated. The DDB1 interaction (PMID:35271311; also PMID:20223979 IPI with
    DDB1 Q16531) is biologically meaningful (defines complex membership) but the GO term used
    is still uninformative "protein binding"; the meaningful content is captured by the
    Cul4-RING complex part_of annotations and the substrate-adaptor MF.

Proposed MF term

  • The current annotation set has NO molecular function term capturing CRBN's actual role.
    GO:1990756 "ubiquitin-like ligase-substrate adaptor activity" is the precise MF for the
    substrate-receptor function and is proposed as a new term.

Caution / non-function

  • Lon N-terminal domain present but NO protease activity (ATP-binding and catalytic domains
    absent) โ€” UniProt CAUTION. Do not annotate peptidase activity.

Pn Notes

(CRBN-pn-notes.md)

CRBN PN Consistency Notes

  • Generated: 2026-06-18
  • Project: PROTEOSTASIS
  • Scope: PN consistency rereview against local AIGR review and available deep-research artifacts
  • UniProt: Q96SW2
  • AIGR review status: COMPLETE
  • Review batch: proteostasis-batch-2026-06-07
  • Batch change status: added

Source Files Checked

Deep Research Files

  • No *-deep-research*.md file found in this gene directory.

AIGR Review Snapshot

  • Description: CRBN (cereblon) is the substrate-recognition subunit of a CRL4 cullin-RING E3 ubiquitin ligase, the DCX/CRL4(CRBN) complex composed of DDB1, CUL4A or CUL4B, RBX1 and CRBN. Through an N-terminal Lon-protease-like domain it binds the adaptor DDB1, and through a C-terminal thalidomide-binding (CULT) domain that coordinates a structural Zn2+ ion it recruits substrate proteins for ubiquitination and subsequent proteasomal degradation. Endogenous substrates include MEIS2, glutamine synthetase (GLUL) and ILF2, and the complex is required for normal limb outgrowth and FGF8 expression in vertebrates. CRBN also regulates neuronal large-conductance Ca2+-activated potassium (BK) channels via interaction with KCNT1, contributing to presynaptic glutamate release, memory and learning; loss-of-function variants cause autosomal recessive intellectual developmental disorder. The CULT domain is the direct molecular target of thalidomide, lenalidomide and pomalidomide (IMiDs) and of newer molecular-glue and PROTAC degraders, which act as molecular glues that reprogram CRBN substrate specificity to recruit neosubstrates such as IKZF1, IKZF3, SALL4, CK1alpha and GSPT1 for degradation. CRBN is expressed widely and most highly in brain, and localizes to cytoplasm, nucleus and peripheral membranes.
  • Existing/core annotation action counts: ACCEPT: 14; KEEP_AS_NON_CORE: 10; MARK_AS_OVER_ANNOTATED: 8; NEW: 1

PN Consistency Summary

  • Consistency: Consistent and well-judged. Review describes CRBN as the substrate-recognition subunit of CRL4(CRBN) (DDB1/CUL4A or CUL4B/RBX1), with the CULT domain as the IMiD/molecular-glue/neosubstrate-binding module. PN annotation (Cul4 substrate receptor, LON/Yippee/DOC domain family; auxiliary domains IPR003111/IPR004910/IPR004939; ref 17588513) and PN-node mapping align with this exactly.
  • PN story / NEW pressure: PN projects GO:1990756 ubiquitin-like ligase-substrate adaptor activity (verified real OLS; definition "brings together a ubiquitin-like ligase and its substrate"). This is NOT in the current GOA (grep confirms absence) โ€” GOA's only MF is bare GO:0005515. The review independently proposes the SAME term as a NEW IDA annotation (from PMID:26909574). Perfect convergence. Conclusion: ADD GO:1990756 โ€” defensible, verified, and the precise adaptor MF CRBN lacks in GOA.
  • Evidence alignment: PN cites 17588513 (CRBN-domain/cereblon ref). Review's adaptor-MF evidence is PMID:26909574 (+ PMID:25108355, PMID:20223979). Different but compatible anchors, both establishing the substrate-receptor/adaptor role; high-throughput GO:0005515 PMIDs correctly marked over-annotated. No conflict.
  • Verdict: Consistent; PN GO:1990756 adaptor mapping verified, matches review's NEW term, and correctly avoids over-broad CRL4 ligase terms. Recommended edits: none (PN and review already converge on GO:1990756).

Full Consistency Review

  • UniProt: Q96SW2 ยท batch: proteostasis-batch-2026-06-07 ยท review status: COMPLETE
  • PN placement: Ubiquitin Proteasome System | E3 ubiquitin and UBL ligases | Cul4A/Cul4B substrate receptor | non-WD40 | LON, Yippee, DOC ; PN-node mapping: group (Cul4A/Cul4B substrate receptor)=mapped, scope=ok_for_propagation_to_go, GO:1990756 ubiquitin-like ligase-substrate adaptor activity; class (E3 ligases)=context_only, scope=too_broad_to_propagate, GO:0061630 ubiquitin protein ligase activity; subtype/type/branch = no_mapping
  • Consistency: Consistent and well-judged. Review describes CRBN as the substrate-recognition subunit of CRL4(CRBN) (DDB1/CUL4A or CUL4B/RBX1), with the CULT domain as the IMiD/molecular-glue/neosubstrate-binding module. PN annotation (Cul4 substrate receptor, LON/Yippee/DOC domain family; auxiliary domains IPR003111/IPR004910/IPR004939; ref 17588513) and PN-node mapping align with this exactly.
  • PN story / NEW pressure: PN projects GO:1990756 ubiquitin-like ligase-substrate adaptor activity (verified real OLS; definition "brings together a ubiquitin-like ligase and its substrate"). This is NOT in the current GOA (grep confirms absence) โ€” GOA's only MF is bare GO:0005515. The review independently proposes the SAME term as a NEW IDA annotation (from PMID:26909574). Perfect convergence. Conclusion: ADD GO:1990756 โ€” defensible, verified, and the precise adaptor MF CRBN lacks in GOA.
  • Mapping strategy: Correct, and notably careful re the task's CRBN caution. The PN deliberately avoids over-broad CRL4 ligase terms: it marks the E3-ligase class as context_only / too_broad_to_propagate (GO:0061630 not propagated) and propagates only the substrate-receptor group โ†’ GO:1990756 (adaptor, not catalytic ligase). This matches the review, which represents CRBN as adaptor (GO:1990756) + complex membership (GO:0031464/0031465), never as the catalytic ligase. No broadening problem.
  • Evidence alignment: PN cites 17588513 (CRBN-domain/cereblon ref). Review's adaptor-MF evidence is PMID:26909574 (+ PMID:25108355, PMID:20223979). Different but compatible anchors, both establishing the substrate-receptor/adaptor role; high-throughput GO:0005515 PMIDs correctly marked over-annotated. No conflict.
  • Verdict: Consistent; PN GO:1990756 adaptor mapping verified, matches review's NEW term, and correctly avoids over-broad CRL4 ligase terms. Recommended edits: none (PN and review already converge on GO:1990756).

PN Dossier Context

  • review_batch: proteostasis-batch-2026-06-07
  • review_yaml: genes/human/CRBN/CRBN-ai-review.yaml
  • PN workbook rows: 1

PN row 1: Ubiquitin Proteasome System | E3 ubiquitin and UBL ligases | Cul4A/Cul4B substrate receptor | non-WD40 | LON, Yippee, DOC

  • UniProt: Q96SW2
  • In branches: UPS
  • Signature domains: (none)
  • Auxiliary domains: IPR003111, IPR004910, IPR004939
  • PN references (titles):
    • 17588513 rev
  • PN-node mapping records (path + ancestors):
    • [subtype] Ubiquitin Proteasome System|E3 ubiquitin and UBL ligases|Cul4A/Cul4B substrate receptor|non-WD40|LON, Yippee, DOC
      status=no_mapping scope= GO=[]
      rationale: Reviewed as a narrower substrate-receptor, adaptor, domain, or family subdivision already covered by the curated parent adaptor/receptor mapping. No additional direct GO mapping is needed at this node.
    • [type] Ubiquitin Proteasome System|E3 ubiquitin and UBL ligases|Cul4A/Cul4B substrate receptor|non-WD40
      status=no_mapping scope= GO=[]
      rationale: Reviewed as a narrower substrate-receptor, adaptor, domain, or family subdivision already covered by the curated parent adaptor/receptor mapping. No additional direct GO mapping is needed at this node.
    • [group] Ubiquitin Proteasome System|E3 ubiquitin and UBL ligases|Cul4A/Cul4B substrate receptor
      status=mapped scope=ok_for_propagation_to_go GO=[GO:1990756 ubiquitin-like ligase-substrate adaptor activity]
      rationale: This PN group captures substrate receptors/adaptors for cullin/UBL ligase systems. The shared GO molecular-function target is ubiquitin-like ligase-substrate adaptor activity.
    • [class] Ubiquitin Proteasome System|E3 ubiquitin and UBL ligases
      status=context_only scope=too_broad_to_propagate GO=[GO:0061630 ubiquitin protein ligase activity]
      rationale: This class is a genuine E3-ligase context, but its descendants include catalytic ligases, cullin scaffolds, substrate receptors, adaptors, cofactors, regulators, and UBL modifier systems. A class-level propagation would over-annotate.
    • [branch] Ubiquitin Proteasome System
      status=no_mapping scope= GO=[]
      rationale: Reviewed as the top-level UPS branch. It is a project taxonomy umbrella rather than a direct GO assertion; UPS propagation must come from manually curated child nodes.

Projected GO annotations (1)

  • GO:1990756 ubiquitin-like ligase-substrate adaptor activity | scope=ok_for_propagation_to_go | goa_status=new_to_goa | from=Ubiquitin Proteasome System|E3 ubiquitin and UBL ligases|Cul4A/Cul4B substrate receptor

Note

This file is generated from the current PROTEOSTASIS phase-1 dossier and local gene-review artifacts. Edit the source review, PN mapping, or dossier rather than this generated note when correcting the underlying curation.

๐Ÿ“„ View Raw YAML

id: Q96SW2
gene_symbol: CRBN
product_type: PROTEIN
status: COMPLETE
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: CRBN (cereblon) is the substrate-recognition subunit of a CRL4 cullin-RING
  E3 ubiquitin ligase, the DCX/CRL4(CRBN) complex composed of DDB1, CUL4A or CUL4B,
  RBX1 and CRBN. Through an N-terminal Lon-protease-like domain it binds the adaptor
  DDB1, and through a C-terminal thalidomide-binding (CULT) domain that coordinates
  a structural Zn2+ ion it recruits substrate proteins for ubiquitination and subsequent
  proteasomal degradation. Endogenous substrates include MEIS2, glutamine synthetase
  (GLUL) and ILF2, and the complex is required for normal limb outgrowth and FGF8
  expression in vertebrates. CRBN also regulates neuronal large-conductance Ca2+-activated
  potassium (BK) channels via interaction with KCNT1, contributing to presynaptic
  glutamate release, memory and learning; loss-of-function variants cause autosomal
  recessive intellectual developmental disorder. The CULT domain is the direct molecular
  target of thalidomide, lenalidomide and pomalidomide (IMiDs) and of newer molecular-glue
  and PROTAC degraders, which act as molecular glues that reprogram CRBN substrate
  specificity to recruit neosubstrates such as IKZF1, IKZF3, SALL4, CK1alpha and GSPT1
  for degradation. CRBN is expressed widely and most highly in brain, and localizes
  to cytoplasm, nucleus and peripheral membranes.
alternative_products:
- name: '1'
  id: Q96SW2-1
- name: '2'
  id: Q96SW2-2
  sequence_note: VSP_015209
existing_annotations:
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: is_active_in
  review:
    summary: CRBN is found in the nucleus as well as the cytoplasm by direct immunolocalization,
      consistent with this phylogenetic transfer.
    action: ACCEPT
    reason: Nuclear localization is supported by direct experimental evidence (PMID:20223979,
      IDA) and is consistent with the substrate-receptor role; the IBA transfer to
      nucleus is reasonable. It is a localization rather than the core molecular function.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: CRBN is a thalidomide-binding protein that forms an E3 ubiquitin
        ligase complex with DDB1 and Cul4A; subcellular localization studies place
        it in the nucleus and cytoplasm.
      full_text_unavailable: true
      reference_section_type: ABSTRACT
- term:
    id: GO:0030177
    label: positive regulation of Wnt signaling pathway
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: involved_in
  review:
    summary: CRBN promotes Wnt-induced, IMiD-independent degradation of CK1alpha (a
      negative regulator of Wnt), and is required for physiological Wnt signaling
      with conserved Wnt phenotypes in zebrafish and Drosophila.
    action: KEEP_AS_NON_CORE
    reason: This regulatory role is experimentally supported (PMID:34489457) and conserved,
      so the phylogenetic transfer is justified, but it is a downstream physiological
      consequence of the E3-ligase activity rather than CRBN's core substrate-receptor
      function.
    supported_by:
    - reference_id: PMID:34489457
      supporting_text: CRBN is required for physiological Wnt signaling, as modulation
        of CRBN in zebrafish and Drosophila yields Wnt-driven phenotypes.
      reference_section_type: ABSTRACT
- term:
    id: GO:0043161
    label: proteasome-mediated ubiquitin-dependent protein catabolic process
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: involved_in
  review:
    summary: As the substrate receptor of CRL4(CRBN), CRBN targets substrates for
      ubiquitination and proteasomal degradation; this is a core biological process
      for the gene.
    action: ACCEPT
    reason: Directly supported by experimental evidence (PMID:20223979 IMP; PMID:26131937
      showing cullin/proteasome-dependent substrate degradation) and a central function.
    supported_by:
    - reference_id: PMID:26131937
      supporting_text: The lenalidomide-dependent decrease in CK1alpha protein level
        was abrogated by treatment with the proteasome inhibitor MG132 and the NEDD8-activating
        enzyme inhibitor MLN4924, which interferes with the activity of cullin-RING
        E3 ubiquitin ligases, implicating proteasome- and cullin-dependent degradation
        of CK1alpha.
      reference_section_type: RESULTS
- term:
    id: GO:0060173
    label: limb development
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: involved_in
  review:
    summary: The CRBN-containing CRL4 complex is required for normal limb outgrowth
      and FGF8 expression in zebrafish and chicks; thalidomide inhibition of this
      activity underlies its teratogenic limb defects.
    action: KEEP_AS_NON_CORE
    reason: This developmental phenotype is supported (PMID:20223979) and explains
      thalidomide teratogenicity, but it is a tissue/developmental consequence of
      the core E3-ligase function rather than the molecular function itself.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: CRBN forms an E3 ubiquitin ligase complex with damaged DNA
        binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and
        expression of the fibroblast growth factor Fgf8 in zebrafish and chicks.
      reference_section_type: ABSTRACT
- term:
    id: GO:0031464
    label: Cul4A-RING E3 ubiquitin ligase complex
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: part_of
  review:
    summary: CRBN is the substrate-receptor component of the CUL4A-RBX1-DDB1-CRBN
      (CRL4) E3 ubiquitin ligase complex.
    action: ACCEPT
    reason: Core, well-established complex membership supported by direct experimental
      and structural evidence (PMID:20223979 IDA, PMID:25108355).
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: CRBN forms an E3 ubiquitin ligase complex with damaged DNA
        binding protein 1 (DDB1) and Cul4A.
      reference_section_type: ABSTRACT
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  qualifier: located_in
  review:
    summary: Nuclear localization, transferred from UniProt subcellular location;
      corroborated by direct immunolocalization (PMID:20223979).
    action: ACCEPT
    reason: Redundant with the experimentally supported IDA nucleus annotation; localization,
      not core function.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: Subcellular localization analysis showed CRBN in the nucleus
        and cytoplasm.
      full_text_unavailable: true
      reference_section_type: ABSTRACT
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  qualifier: located_in
  review:
    summary: Cytoplasmic localization, transferred from UniProt subcellular location;
      corroborated by direct immunolocalization (PMID:20223979).
    action: ACCEPT
    reason: Redundant with the experimentally supported IDA cytoplasm annotation;
      localization, not core function.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: Subcellular localization analysis showed CRBN in the nucleus
        and cytoplasm.
      full_text_unavailable: true
      reference_section_type: ABSTRACT
- term:
    id: GO:0016020
    label: membrane
  evidence_type: IEA
  original_reference_id: GO_REF:0000044
  qualifier: located_in
  review:
    summary: CRBN is annotated as a peripheral membrane protein (by similarity), consistent
      with its interaction with membrane ion channels such as KCNT1/BK channels.
    action: KEEP_AS_NON_CORE
    reason: The very general "membrane" term reflects a peripheral membrane association
      (by similarity, UniProt) related to its channel-regulatory role; retained as
      a non-core location but uninformative as to function.
    supported_by:
    - reference_id: file:human/CRBN/CRBN-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Membrane; Peripheral
        membrane protein.'
      reference_section_type: OTHER
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:25416956
  qualifier: enables
  review:
    summary: Bare protein binding from a high-throughput binary interactome map (HuRI),
      reporting interactions with RBPMS and PAK5.
    action: MARK_AS_OVER_ANNOTATED
    reason: GO:0005515 protein binding is uninformative and these high-throughput
      interactors (RBPMS, PAK5) have no established functional relationship to CRBN's
      E3-ligase role; per curation guidance bare protein binding should not be retained
      as informative.
    supported_by:
    - reference_id: PMID:25416956
      supporting_text: >-
        A proteome-scale map of the human interactome network.
      reference_section_type: ABSTRACT
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:26131937
  qualifier: enables
  review:
    summary: Protein-binding annotation derived from the lenalidomide study; the interactors
      are DDB1 (complex partner) and CK1alpha (a strictly IMiD-induced neosubstrate).
    action: MARK_AS_OVER_ANNOTATED
    reason: The underlying interactions are biologically meaningful (DDB1 defines
      complex membership; CK1alpha is a lenalidomide-induced neosubstrate), but the
      generic protein binding term is uninformative; the meaningful content is captured
      by the CRL4 complex-membership and ubiquitination/catabolism annotations and
      proposed substrate-adaptor MF.
    supported_by:
    - reference_id: PMID:26131937
      supporting_text: Lenalidomide induces the ubiquitination of casein kinase 1A1
        (CK1alpha) by the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4(CRBN)).
      reference_section_type: ABSTRACT
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:26909574
  qualifier: enables
  review:
    summary: Protein-binding annotation from the structural study of the DDB1-CRBN-lenalidomide-CK1alpha
      complex; interactors are DDB1 and the IMiD-dependent neosubstrate CK1alpha.
    action: MARK_AS_OVER_ANNOTATED
    reason: CK1alpha binding to CRL4(CRBN) is strictly IMiD-dependent (a drug-induced
      neosubstrate), and DDB1 binding is captured by complex membership; the generic
      protein binding term itself is uninformative.
    supported_by:
    - reference_id: PMID:26909574
      supporting_text: We show that CK1alpha binding to CRL4(CRBN) is strictly dependent
        on the presence of an IMiD.
      reference_section_type: ABSTRACT
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:31515488
  qualifier: enables
  review:
    summary: Bare protein binding from a large-scale interaction-perturbation screen,
      reporting an interaction with PAK5.
    action: MARK_AS_OVER_ANNOTATED
    reason: Uninformative generic term from a high-throughput screen with no established
      functional link to CRBN biology.
    supported_by:
    - reference_id: PMID:31515488
      supporting_text: >-
        Extensive disruption of protein interactions by genetic variants across the allele
        frequency spectrum in human populations.
      reference_section_type: ABSTRACT
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:32296183
  qualifier: enables
  review:
    summary: Bare protein binding from a binary human interactome reference map (HuRI),
      reporting an interaction with MISP.
    action: MARK_AS_OVER_ANNOTATED
    reason: Uninformative generic term from a high-throughput map with no established
      functional relationship to CRBN.
    supported_by:
    - reference_id: PMID:32296183
      supporting_text: >-
        A reference map of the human binary protein interactome.
      reference_section_type: ABSTRACT
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:32814053
  qualifier: enables
  review:
    summary: Bare protein binding from a neurodegenerative-disease interactome screen,
      reporting interactions with PMP22, KLF11 and COL26A1.
    action: MARK_AS_OVER_ANNOTATED
    reason: Uninformative generic term from a high-throughput screen with no established
      functional link to CRBN's E3-ligase function.
    supported_by:
    - reference_id: PMID:32814053
      supporting_text: Interactome mapping providing a network of neurodegenerative-disease
        proteins, reporting CRBN interactions including with PMP22, KLF11 and COL26A1.
      full_text_unavailable: true
      reference_section_type: ABSTRACT
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:35271311
  qualifier: enables
  review:
    summary: Protein-binding annotation from the OpenCell endogenous-tagging study,
      reporting interaction with DDB1.
    action: MARK_AS_OVER_ANNOTATED
    reason: The DDB1 interaction is biologically central (it defines CRBN's incorporation
      into CRL4), but the generic protein binding term is uninformative; complex membership
      is already captured by the Cul4-RING complex annotations.
    supported_by:
    - reference_id: PMID:35271311
      supporting_text: >-
        OpenCell: Endogenous tagging for the cartography of human cellular organization.
      reference_section_type: ABSTRACT
- term:
    id: GO:0031333
    label: negative regulation of protein-containing complex assembly
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: involved_in
  review:
    summary: Transferred by orthology from rat Crbn (Q56AP7), reflecting CRBN's regulation
      of BK channel assembly/surface expression via KCNT1.
    action: KEEP_AS_NON_CORE
    reason: The underlying biology (CRBN regulating ion-channel complex assembly)
      is supported in rodent models, but this is a peripheral neuronal role transferred
      by orthology, not the core E3-ligase function.
    supported_by:
    - reference_id: file:human/CRBN/CRBN-uniprot.txt
      supporting_text: Likely to function by regulating the assembly and neuronal
        surface expression of BK channels via its interaction with KCNT1.
      reference_section_type: OTHER
- term:
    id: GO:0031334
    label: positive regulation of protein-containing complex assembly
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: involved_in
  review:
    summary: Transferred by orthology from rat Crbn (Q56AP7); reflects CRBN's role
      in BK channel assembly/surface expression.
    action: KEEP_AS_NON_CORE
    reason: As with the negative-regulation counterpart, this is an ortholog-transferred
      peripheral neuronal role rather than the core E3 function; retained as non-core.
    supported_by:
    - reference_id: file:human/CRBN/CRBN-uniprot.txt
      supporting_text: Likely to function by regulating the assembly and neuronal
        surface expression of BK channels via its interaction with KCNT1.
      reference_section_type: OTHER
- term:
    id: GO:0034766
    label: negative regulation of monoatomic ion transmembrane transport
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: involved_in
  review:
    summary: CRBN negatively regulates large-conductance Ca2+-activated K+ (BK) channels,
      maintaining presynaptic glutamate release and cognition; annotation transferred
      by orthology from rat Crbn.
    action: KEEP_AS_NON_CORE
    reason: Supported by rodent functional studies (PMID:29530986; UniProt FUNCTION)
      and explains MRT2-related cognitive phenotypes, but is a distinct neuronal role
      separate from the core E3-ligase function.
    supported_by:
    - reference_id: file:human/CRBN/CRBN-uniprot.txt
      supporting_text: Maintains presynaptic glutamate release and consequently cognitive
        functions, such as memory and learning, by negatively regulating large-conductance
        calcium-activated potassium (BK) channels in excitatory neurons.
      reference_section_type: OTHER
- term:
    id: GO:0035641
    label: locomotory exploration behavior
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: involved_in
  review:
    summary: Behavioral term transferred by orthology from mouse Crbn (Q8C7D2).
    action: KEEP_AS_NON_CORE
    reason: Reflects organism-level behavioral phenotypes of rodent Crbn (consistent
      with CRBN's neuronal/BK-channel role) but is far removed from the molecular
      function and rests only on ortholog transfer.
    supported_by:
    - reference_id: file:human/CRBN/CRBN-uniprot.txt
      supporting_text: May also be involved in regulating anxiety-like behaviors via
        a BK channel-independent mechanism (By similarity).
      reference_section_type: OTHER
- term:
    id: GO:0044325
    label: transmembrane transporter binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: enables
  review:
    summary: Reflects CRBN's interaction with the KCNT1 channel and the BK channel,
      transferred by orthology from rat Crbn.
    action: KEEP_AS_NON_CORE
    reason: A more informative MF than bare protein binding (channel binding underlies
      CRBN's neuronal role) and supported by interaction data, but peripheral to the
      core substrate-receptor function and based on ortholog transfer.
    supported_by:
    - reference_id: file:human/CRBN/CRBN-uniprot.txt
      supporting_text: Likely to function by regulating the assembly and neuronal
        surface expression of BK channels via its interaction with KCNT1.
      reference_section_type: OTHER
- term:
    id: GO:0048471
    label: perinuclear region of cytoplasm
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: located_in
  review:
    summary: Perinuclear cytoplasmic localization transferred by orthology from rat
      Crbn.
    action: KEEP_AS_NON_CORE
    reason: A plausible sub-cytoplasmic localization consistent with the experimentally
      supported cytoplasm annotation, but based only on ortholog transfer and not
      core function.
    supported_by:
    - reference_id: file:human/CRBN/CRBN-uniprot.txt
      supporting_text: 'SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Membrane; Peripheral
        membrane protein.'
      reference_section_type: OTHER
- term:
    id: GO:0016567
    label: protein ubiquitination
  evidence_type: IEA
  original_reference_id: GO_REF:0000041
  qualifier: involved_in
  review:
    summary: As the substrate receptor of CRL4(CRBN), CRBN mediates ubiquitination
      of target proteins; this UniPathway-mapped term is a core process.
    action: ACCEPT
    reason: Directly supported by experimental evidence (PMID:20223979 IMP) and central
      to CRBN function.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: >-
        CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and
        Cul4A that is important for limb outgrowth and expression of the fibroblast growth
        factor Fgf8 in zebrafish and chicks.
      reference_section_type: ABSTRACT
- term:
    id: GO:0031464
    label: Cul4A-RING E3 ubiquitin ligase complex
  evidence_type: NAS
  original_reference_id: PMID:25108355
  qualifier: part_of
  review:
    summary: CRBN is a component of the CUL4A variant CRL4-CRBN E3 ubiquitin ligase
      complex (ComplexPortal CPX-2759).
    action: ACCEPT
    reason: Core complex membership; structurally and biochemically established (PMID:25108355
      Cul4-Rbx1-DDB1-Cereblon complex). Redundant with the IDA annotation to the
      same term.
    supported_by:
    - reference_id: PMID:25108355
      supporting_text: The Cul4-Rbx1-DDB1-Cereblon E3 ubiquitin ligase complex is
        the target of thalidomide, lenalidomide and pomalidomide.
      reference_section_type: ABSTRACT
- term:
    id: GO:0031465
    label: Cul4B-RING E3 ubiquitin ligase complex
  evidence_type: NAS
  original_reference_id: PMID:25108355
  qualifier: part_of
  review:
    summary: CRBN is also a component of the CUL4B variant CRL4-CRBN E3 ubiquitin
      ligase complex (ComplexPortal CPX-2762).
    action: ACCEPT
    reason: CRBN can assemble with either CUL4A or CUL4B; the CUL4B-variant complex
      is documented in ComplexPortal and is a valid core complex membership.
    supported_by:
    - reference_id: file:human/CRBN/CRBN-uniprot.txt
      supporting_text: ComplexPortal; CPX-2762; CRL4-CRBN E3 ubiquitin ligase complex,
        CUL4B variant.
      reference_section_type: OTHER
- term:
    id: GO:0030177
    label: positive regulation of Wnt signaling pathway
  evidence_type: IMP
  original_reference_id: PMID:34489457
  qualifier: involved_in
  review:
    summary: CRBN mediates Wnt-induced, IMiD-independent degradation of CK1alpha (a
      negative regulator of Wnt) and is required for physiological Wnt signaling.
    action: KEEP_AS_NON_CORE
    reason: Experimentally supported (PMID:34489457) and conserved, but a downstream
      physiological consequence of the E3-ligase activity rather than CRBN's core
      molecular function.
    supported_by:
    - reference_id: PMID:34489457
      supporting_text: >-
        Herein we demonstrate that Wnt, the extracellular ligand of an essential signal
        transduction pathway, promotes the CRBN-dependent degradation of a subset of proteins.
      reference_section_type: ABSTRACT
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-9681169
  qualifier: located_in
  review:
    summary: Cytosolic localization from Reactome (CRBN binds IMiDs), consistent with
      the experimentally supported cytoplasm annotation.
    action: ACCEPT
    reason: Consistent with direct cytoplasmic localization data; a localization rather
      than core function.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: Subcellular localization analysis showed CRBN in the nucleus
        and cytoplasm.
      full_text_unavailable: true
      reference_section_type: ABSTRACT
- term:
    id: GO:0043161
    label: proteasome-mediated ubiquitin-dependent protein catabolic process
  evidence_type: IMP
  original_reference_id: PMID:20223979
  qualifier: involved_in
  review:
    summary: CRBN, as the substrate receptor of CRL4(CRBN), directs substrates for
      ubiquitin-dependent proteasomal degradation; a core process.
    action: ACCEPT
    reason: Directly supported by experimental evidence; central to CRBN function.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: >-
        CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and
        Cul4A that is important for limb outgrowth and expression of the fibroblast growth
        factor Fgf8 in zebrafish and chicks.
      reference_section_type: ABSTRACT
- term:
    id: GO:0031464
    label: Cul4A-RING E3 ubiquitin ligase complex
  evidence_type: IDA
  original_reference_id: PMID:20223979
  qualifier: part_of
  review:
    summary: CRBN was directly shown to form a DCX/CRL4 complex with DDB1, RBX1 and
      CUL4A.
    action: ACCEPT
    reason: Core complex membership supported by direct experimental identification
      of the DCX complex.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: CRBN forms an E3 ubiquitin ligase complex with damaged DNA
        binding protein 1 (DDB1) and Cul4A.
      reference_section_type: ABSTRACT
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:20223979
  qualifier: enables
  review:
    summary: Protein-binding annotation capturing the direct CRBN-DDB1 interaction
      that incorporates CRBN into the CRL4 complex.
    action: MARK_AS_OVER_ANNOTATED
    reason: The DDB1 interaction is biologically central but the generic protein binding
      term is uninformative; complex membership is already captured by the Cul4-RING
      complex annotations, and the adaptor MF is better represented by the proposed
      substrate-adaptor term.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: CRBN forms an E3 ubiquitin ligase complex with damaged DNA
        binding protein 1 (DDB1) and Cul4A.
      reference_section_type: ABSTRACT
- term:
    id: GO:0005634
    label: nucleus
  evidence_type: IDA
  original_reference_id: PMID:20223979
  qualifier: located_in
  review:
    summary: Direct immunolocalization places CRBN in the nucleus.
    action: ACCEPT
    reason: Experimentally supported localization (IDA); a location rather than the
      core function.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: Subcellular localization analysis showed CRBN in the nucleus
        and cytoplasm.
      full_text_unavailable: true
      reference_section_type: ABSTRACT
- term:
    id: GO:0005737
    label: cytoplasm
  evidence_type: IDA
  original_reference_id: PMID:20223979
  qualifier: located_in
  review:
    summary: Direct immunolocalization places CRBN in the cytoplasm; CRBN acts in
      both the nucleus and cytoplasm, consistent with substrate degradation in both
      compartments.
    action: ACCEPT
    reason: Experimentally supported localization (IDA); a location rather than the
      core function. The dual nucleus/cytoplasm distribution is further corroborated
      by the falcon deep research synthesis.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: Subcellular localization analysis showed CRBN in the nucleus
        and cytoplasm.
      full_text_unavailable: true
      reference_section_type: ABSTRACT
    - reference_id: file:human/CRBN/CRBN-deep-research-falcon.md
      supporting_text: Cereblon is localized in both the nucleus and cytoplasm, enabling
        it to ubiquitinate and degrade substrates in multiple cellular compartments
      reference_section_type: OTHER
- term:
    id: GO:0016567
    label: protein ubiquitination
  evidence_type: IMP
  original_reference_id: PMID:20223979
  qualifier: involved_in
  review:
    summary: CRBN mediates ubiquitination of target proteins as the substrate receptor
      of CRL4(CRBN); a core process.
    action: ACCEPT
    reason: Directly supported by experimental evidence (IMP) and central to CRBN
      function.
    supported_by:
    - reference_id: PMID:20223979
      supporting_text: >-
        CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and
        Cul4A that is important for limb outgrowth and expression of the fibroblast growth
        factor Fgf8 in zebrafish and chicks.
      reference_section_type: ABSTRACT
- term:
    id: GO:1990756
    label: ubiquitin-like ligase-substrate adaptor activity
  evidence_type: IDA
  original_reference_id: PMID:26909574
  qualifier: enables
  review:
    summary: CRBN is the substrate receptor/adaptor of the CRL4(CRBN) E3 ubiquitin
      ligase, recruiting substrates (and drug-induced neosubstrates) for ubiquitination.
      It has no intrinsic catalytic activity but confers substrate specificity to
      the complex.
    action: NEW
    reason: The existing GOA set lacks any molecular function term for CRBN's actual
      role. GO:1990756 ubiquitin-like ligase-substrate adaptor activity is the precise,
      well-supported MF and is proposed as a new annotation. The substrate-adaptor
      (non-catalytic) nature is corroborated by the falcon deep research synthesis.
    proposed_replacement_terms:
    - id: GO:1990756
      label: ubiquitin-like ligase-substrate adaptor activity
    supported_by:
    - reference_id: PMID:26909574
      supporting_text: IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN
        (also known as CRL4(CRBN)) E3 ubiquitin ligase.
      reference_section_type: ABSTRACT
    - reference_id: file:human/CRBN/CRBN-deep-research-falcon.md
      supporting_text: CRBN does not possess enzymatic activity itself but rather acts
        as an adapter protein that confers substrate specificity to the ubiquitination
        machinery
      reference_section_type: OTHER
core_functions:
- description: CRBN is the substrate-recognition subunit of the CRL4(CRBN) cullin-RING
    E3 ubiquitin ligase, binding DDB1 through its N-terminal Lon-like domain and recruiting
    substrate proteins through its C-terminal CULT (thalidomide-binding) domain to
    direct their ubiquitination and proteasomal degradation.
  molecular_function:
    id: GO:1990756
    label: ubiquitin-like ligase-substrate adaptor activity
  directly_involved_in:
  - id: GO:0016567
    label: protein ubiquitination
  - id: GO:0043161
    label: proteasome-mediated ubiquitin-dependent protein catabolic process
  locations:
  - id: GO:0005737
    label: cytoplasm
  - id: GO:0005634
    label: nucleus
  in_complex:
    id: GO:0031464
    label: Cul4A-RING E3 ubiquitin ligase complex
  supported_by:
  - reference_id: PMID:20223979
    supporting_text: CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding
      protein 1 (DDB1) and Cul4A.
    reference_section_type: ABSTRACT
  - reference_id: PMID:26909574
    supporting_text: IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN
      (also known as CRL4(CRBN)) E3 ubiquitin ligase.
    reference_section_type: ABSTRACT
- description: CRBN binds thalidomide-class drugs (thalidomide, lenalidomide, pomalidomide)
    and molecular-glue/PROTAC degraders in its CULT domain; drug binding acts as a
    molecular glue that reprograms CRBN substrate specificity to recruit neosubstrates
    (e.g. IKZF1, IKZF3, CK1alpha) for degradation. This neosubstrate recruitment is
    drug-induced rather than an endogenous function.
  molecular_function:
    id: GO:1990756
    label: ubiquitin-like ligase-substrate adaptor activity
  supported_by:
  - reference_id: PMID:25108355
    supporting_text: These drugs directly bind Cereblon (CRBN) and promote the recruitment
      of substrates Ikaros (IKZF1) and Aiolos (IKZF3) to the E3 complex, thus leading
      to substrate ubiquitination and degradation.
    reference_section_type: ABSTRACT
  - reference_id: PMID:26909574
    supporting_text: IMiDs also repurpose the ligase to target new proteins for degradation.
    reference_section_type: ABSTRACT
proposed_new_terms: []
suggested_questions:
- question: Beyond MEIS2, GLUL and ILF2, what is the full endogenous (IMiD-independent)
    substrate repertoire of human CRL4(CRBN), and which degrons does CRBN recognize
    natively?
  experts:
  - Handa H
  - Ebert BL
- question: Is CRBN's regulation of BK/KCNT1 channels mediated by ubiquitination of
    a channel-associated substrate, or by a non-degradative scaffolding mechanism?
  experts:
  - Choi SY
  - Park CS
suggested_experiments:
- hypothesis: CRBN has a defined set of endogenous neosubstrate-independent substrates
    whose stabilization explains the developmental phenotypes seen on CRBN loss.
  description: Perform global diGly (K-epsilon-GG) ubiquitinome and quantitative proteomics
    comparing CRBN-knockout and wild-type human cells in the absence of any IMiD,
    to define drug-independent CRL4(CRBN) substrates.
  experiment_type: ubiquitinome and degradation proteomics
- hypothesis: CRBN regulates BK channel surface expression through the CRL4 ubiquitin
    ligase activity rather than a degradation-independent scaffold function.
  description: Compare BK/KCNT1 channel surface expression and current in neurons
    expressing wild-type CRBN, a DDB1-binding-deficient mutant, and a ligase-dead
    CRL4 context, using surface biotinylation and electrophysiology.
  experiment_type: electrophysiology and surface-expression assay
references:
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
  findings: []
- id: GO_REF:0000041
  title: Gene Ontology annotation based on UniPathway vocabulary mapping
  findings: []
- id: GO_REF:0000044
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular Location
    vocabulary mapping, accompanied by conservative changes to GO terms applied by
    UniProt
  findings: []
- id: GO_REF:0000107
  title: Automatic transfer of experimentally verified manual GO annotation data to
    orthologs using Ensembl Compara
  findings: []
- id: PMID:20223979
  title: Identification of a primary target of thalidomide teratogenicity.
  findings:
  - statement: CRBN forms a CRL4 E3 ubiquitin ligase with DDB1 and Cul4A required
      for limb outgrowth and FGF8 expression; thalidomide binds CRBN and inhibits
      this ligase activity.
    supporting_text: CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding
      protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression
      of the fibroblast growth factor Fgf8 in zebrafish and chicks.
    reference_section_type: ABSTRACT
- id: PMID:25108355
  title: Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for
    responsiveness to thalidomide analogs.
  findings:
  - statement: The Cul4-Rbx1-DDB1-Cereblon E3 ubiquitin ligase is the target of IMiDs,
      which bind CRBN and promote recruitment of IKZF1/IKZF3 for ubiquitination and
      degradation.
    supporting_text: These drugs directly bind Cereblon (CRBN) and promote the recruitment
      of substrates Ikaros (IKZF1) and Aiolos (IKZF3) to the E3 complex, thus leading
      to substrate ubiquitination and degradation.
    reference_section_type: ABSTRACT
- id: PMID:25416956
  title: A proteome-scale map of the human interactome network.
  findings: []
- id: PMID:26131937
  title: Lenalidomide induces ubiquitination and degradation of CK1ฮฑ in del(5q) MDS.
  findings:
  - statement: Lenalidomide induces CRL4(CRBN)-dependent, proteasome- and cullin-dependent
      ubiquitination and degradation of CK1alpha.
    supporting_text: Lenalidomide induces the ubiquitination of casein kinase 1A1
      (CK1alpha) by the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4(CRBN)),
      resulting in CK1alpha degradation.
    reference_section_type: ABSTRACT
- id: PMID:26909574
  title: Structural basis of lenalidomide-induced CK1ฮฑ degradation by the CRL4(CRBN)
    ubiquitin ligase.
  findings:
  - statement: CRBN is the substrate receptor of CRL4(CRBN); CK1alpha binding is strictly
      IMiD-dependent, illustrating drug-induced neosubstrate recruitment.
    supporting_text: We show that CK1alpha binding to CRL4(CRBN) is strictly dependent
      on the presence of an IMiD.
    reference_section_type: ABSTRACT
- id: PMID:31515488
  title: Extensive disruption of protein interactions by genetic variants across the
    allele frequency spectrum in human populations.
  findings: []
- id: PMID:32296183
  title: A reference map of the human binary protein interactome.
  findings: []
- id: PMID:32814053
  title: Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins
    and Uncovers Widespread Protein Aggregation in Affected Brains.
  findings: []
- id: PMID:34489457
  title: The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved
    regulator of Wnt signaling.
  findings:
  - statement: CRBN mediates Wnt-induced, IMiD-independent degradation of CK1alpha
      and is required for physiological Wnt signaling.
    supporting_text: Wnt promotes the CRBN-dependent degradation of a subset of proteins.
      These substrates include Casein kinase 1alpha (CK1alpha), a negative regulator
      of Wnt signaling.
    reference_section_type: ABSTRACT
- id: PMID:35271311
  title: 'OpenCell: Endogenous tagging for the cartography of human cellular organization.'
  findings: []
- id: Reactome:R-HSA-9681169
  title: CRBN binds IMiDs
  findings: []
- id: file:human/CRBN/CRBN-deep-research-falcon.md
  title: Falcon deep research report for CRBN
  reference_review:
    relevance: HIGH
    correctness: UNVERIFIED
    review_notes: 'LLM-synthesized deep-research report (Edison/falcon). Cited using
      author-year keys rather than resolvable PMIDs, so individual citations could
      not be confirmed against cached publications; marked UNVERIFIED. Content is
      consistent with the established picture: it correctly frames CRBN as a non-catalytic
      substrate-receptor/adaptor of CRL4(CRBN) and explicitly distinguishes endogenous
      substrates (MEIS2, SLO1/KCNMA1, ILF2) from drug-induced neosubstrates (IKZF1/3,
      CK1alpha, GSPT1, SALL4) recruited only in the presence of IMiDs/CELMoDs. It
      adds mechanistic detail on G-loop degron recognition and open/closed conformational
      dynamics that is drug-/neosubstrate-centric and should not be over-interpreted
      as endogenous function. Used here to corroborate the substrate-adaptor molecular
      function and dual nucleus/cytoplasm localization, not to alter any experimental
      annotation.'
  findings:
  - statement: CRBN is a non-catalytic substrate-recognition adaptor of the CRL4(CRBN)
      E3 ubiquitin ligase that confers substrate specificity to the ubiquitination
      machinery.
    supporting_text: CRBN does not possess enzymatic activity itself but rather acts
      as an adapter protein that confers substrate specificity to the ubiquitination
      machinery
    reference_section_type: OTHER